x | Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 |
o | Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
Delaware | 77-0160744 |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
3911 Sorrento Valley Boulevard, Suite 110 San Diego, CA | 92121 (Zip Code) |
(Address of principal executive offices) |
Large Accelerated Filer | x | Accelerated Filer | o | |
Non-Accelerated Filer | o | (Do not check if a smaller reporting company) | Smaller Reporting Company | o |
• | Decrease in deferred tax assets by $27.5 million as of June, 30 2016 and December 31, 2015 |
• | Increase in accumulated deficit by $27.5 million as of June 30, 2016 and December 31, 2015 |
• | Increase to current 2019 convertible senior notes, net and decrease to non-current 2019 convertible senior notes, net by $202.0 million as of December 31, 2015 |
• | Increase to temporary equity component of currently redeemable convertible notes and a decrease to additional paid-in capital by $39.6 million as of December 31, 2015 |
PART I. FINANCIAL INFORMATION | ||
Condensed Consolidated Balance Sheets as of March 31, 2016 (restated) and December 31, 2015 (Unaudited) | ||
PART II. OTHER INFORMATION | ||
GLOSSARY OF TERMS AND ABBREVIATIONS | |
Abbreviation | Definition |
2019 Convertible Senior Notes | $245.0 million aggregate principal amount of convertible senior unsecured notes due 2019 |
Amgen | Amgen, Inc. |
AOCI | Accumulated Other Comprehensive Income |
ASC | Accounting Standards Codification |
ASU | Accounting Standards Update |
Company | Ligand Pharmaceuticals Incorporated, including subsidiaries |
CorMatrix | CorMatrix Cardiovascular, Inc. |
CVR | Contingent value right |
CyDex | CyDex Pharmaceuticals, Inc. |
Amended ESPP | Employee Stock Purchase Plan, as amended and restated |
Eisai | Eisai Incorporated |
EMA | European Medicines Agency |
FASB | Financial Accounting Standards Board |
FDA | Food and Drug Administration |
FSGS | Focal segmental glomerulosclerosis |
GAAP | Generally accepted accounting principles in the United States |
IPO | Initial public offering |
IPR&D | In-Process Research and Development |
Ligand | Ligand Pharmaceuticals Incorporated, including subsidiaries |
LSA | Loan and Security Agreement |
Metabasis | Metabasis Therapeutics, Inc. |
MLA | Master License Agreement |
NOLs | Net Operating Losses |
OMT | OMT, Inc. or Open Monoclonal Technology, Inc. |
Par | Par Pharmaceutical, Inc. |
Pfizer | Pfizer Inc. |
Retrophin | Retrophin Inc. |
SEC | Securities and Exchange Commission |
Selexis | Selexis, SA |
TPE | Third-party evidence |
VIE | Variable interest entity |
Viking | Viking Therapeutics |
Viking IPO | Viking's initial public offering |
VSOE | Vendor-specific objective evidence |
PART I. | FINANCIAL INFORMATION |
ITEM 1. | FINANCIAL STATEMENTS |
March 31, 2016 | December 31, 2015 | ||||||
(unaudited) (restated) | (a) (restated) | ||||||
ASSETS | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 31,293 | $ | 97,428 | |||
Short-term investments | 81,908 | 102,791 | |||||
Accounts receivable | 11,779 | 6,170 | |||||
Note receivable from Viking Therapeutics | 4,767 | 4,782 | |||||
Inventory | 1,750 | 1,633 | |||||
Other current assets | 1,562 | 1,908 | |||||
Total current assets | 133,059 | 214,712 | |||||
Deferred income taxes | 129,777 | 189,083 | |||||
Investment in Viking Therapeutics | 28,118 | 29,728 | |||||
Intangible assets, net | 212,823 | 48,347 | |||||
Goodwill | 72,997 | 12,238 | |||||
Commercial license rights | 8,546 | 8,554 | |||||
Property and equipment, net | 567 | 372 | |||||
Other assets | 70 | 27 | |||||
Total assets | $ | 585,957 | $ | 503,061 | |||
LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 2,688 | $ | 4,083 | |||
Accrued liabilities | 3,669 | 5,397 | |||||
Current contingent liabilities | 5,285 | 10,414 | |||||
Current lease exit obligations | 577 | 934 | |||||
2019 convertible senior notes, net | — | 201,985 | |||||
Other current liabilities | 21 | 8 | |||||
Total current liabilities | 12,240 | 222,821 | |||||
Long-term debt, net | 204,653 | — | |||||
Long-term contingent liabilities | 4,022 | 3,033 | |||||
Other long-term liabilities | 446 | 297 | |||||
Total liabilities | 221,361 | 226,151 | |||||
Commitments and Contingencies | |||||||
Equity component of currently redeemable convertible notes (Note 6) | — | 39,628 | |||||
Stockholders' equity: | |||||||
Common stock, $0.001 par value; 33,333,333 shares authorized; 20,815,636 and 19,949,012 shares issued and outstanding at March 31, 2016 and December 31, 2015, respectively | 21 | 20 | |||||
Additional paid-in capital | 783,890 | 661,850 | |||||
Accumulated other comprehensive income | 3,568 | 4,903 | |||||
Accumulated deficit | (422,883 | ) | (429,491 | ) | |||
Total stockholders' equity attributable to Ligand Pharmaceuticals | 364,596 | 237,282 | |||||
Total liabilities and stockholders' equity | $ | 585,957 | $ | 503,061 | |||
(a) See restatement discussion in footnote 1 |
Three months ended | |||||||
March 31, | |||||||
2016 | 2015 | ||||||
Revenues: | |||||||
Royalties | $ | 14,390 | $ | 10,287 | |||
Material sales | 5,341 | 3,729 | |||||
License fees, milestones and other revenues | 9,917 | 586 | |||||
Total revenues | 29,648 | 14,602 | |||||
Operating costs and expenses: | |||||||
Cost of sales (1) | 955 | 1,074 | |||||
Amortization of intangibles | 2,524 | 594 | |||||
Research and development | 4,004 | 3,368 | |||||
General and administrative | 6,825 | 5,994 | |||||
Lease exit and termination costs | 244 | 223 | |||||
Total operating costs and expenses | 14,552 | 11,253 | |||||
Income from operations | 15,096 | 3,349 | |||||
Other (expense) income: | |||||||
Interest expense, net | (3,005 | ) | (2,973 | ) | |||
Increase in contingent liabilities | (1,306 | ) | (3 | ) | |||
Equity in net losses from Viking Therapeutics | (1,605 | ) | — | ||||
Other, net | 391 | (447 | ) | ||||
Total other (expense) income, net | (5,525 | ) | (3,423 | ) | |||
Income (loss) before income taxes | 9,571 | (74 | ) | ||||
Income tax expense | (3,694 | ) | (15 | ) | |||
Income (loss) from operations | 5,877 | (89 | ) | ||||
Discontinued operations: | |||||||
Gain on sale of Oncology Product Line before income taxes | 1,139 | — | |||||
Income tax expense on discontinued operations | (408 | ) | — | ||||
Income from discontinued operations | 731 | — | |||||
Net income (loss) including noncontrolling interests: | 6,608 | (89 | ) | ||||
Less: Net loss attributable to noncontrolling interests | — | (843 | ) | ||||
Net income | $ | 6,608 | $ | 754 | |||
Per share amounts attributable to Ligand common shareholders: | |||||||
Basic earnings per share data | |||||||
Income from continuing operations | $ | 0.28 | $ | 0.04 | |||
Income from discontinued operations | 0.04 | — | |||||
Net income | $ | 0.32 | $ | 0.04 | |||
Diluted earnings per share data(2) | |||||||
Income from continuing operations | $ | 0.26 | $ | 0.04 | |||
Income from discontinued operations | 0.03 | — | |||||
Net income | $ | 0.30 | $ | 0.04 | |||
Shares used for computation (in thousands) | |||||||
Basic | 20,708 | 19,612 | |||||
Diluted | 22,284 | 20,631 |
Three months ended | ||||||||
March 31, | ||||||||
2016 | 2015 | |||||||
Net income: | $ | 6,608 | $ | 754 | ||||
Unrealized net (loss) gain on available-for-sale securities, net of tax | (1,098 | ) | 4,614 | |||||
Less: Reclassification of net realized (gains) losses included in net income, net of tax | (236 | ) | (234 | ) | ||||
Comprehensive income (loss) | $ | 5,274 | $ | 5,134 |
Three months ended | |||||||
March 31, | |||||||
2016 | 2015 | ||||||
Operating activities | |||||||
Net income (loss) including noncontrolling interests | $ | 6,608 | $ | (89 | ) | ||
Less: gain from discontinued operations | 731 | — | |||||
Income (loss) from continuing operations | 5,877 | (89 | ) | ||||
Adjustments to reconcile net income including noncontrolling interests to net cash provided by operating activities: | |||||||
Non-cash change in estimated fair value of contingent liabilities | 1,306 | 3 | |||||
Realized (gain) loss on sale of short-term investment | (406 | ) | 447 | ||||
Depreciation and amortization | 2,575 | 650 | |||||
Amortization of discount on investments, net | 320 | — | |||||
Amortization of debt discount and issuance fees | 2,668 | 2,509 | |||||
Stock-based compensation | 4,118 | 2,914 | |||||
Deferred income taxes | 4,101 | 6 | |||||
Accretion of note payable | — | 14 | |||||
Change in fair value of the convertible debt receivable from Viking | 15 | — | |||||
Loss on equity investment in Viking Therapeutics, Inc. | 1,605 | — | |||||
Other | (1 | ) | |||||
Changes in operating assets and liabilities: | |||||||
Accounts receivable | (5,604 | ) | 5,211 | ||||
Inventory | 853 | (150 | ) | ||||
Other current assets | 16 | 445 | |||||
Other long-term assets | (41 | ) | (291 | ) | |||
Accounts payable and accrued liabilities | (4,302 | ) | (4,667 | ) | |||
Restricted investments | — | 661 | |||||
Deferred revenue | 13 | (83 | ) | ||||
Net cash provided by operating activities | 13,114 | 7,579 | |||||
Investing activities | |||||||
Payments to CVR holders and other contingency payments | (5,446 | ) | (3,247 | ) | |||
Purchases of property and equipment | (238 | ) | (10 | ) | |||
Cash paid for acquisition, net of cash acquired | (92,855 | ) | — | ||||
Purchase of short-term investments | (49,892 | ) | — | ||||
Proceeds from sale of property and equipment | — | 1 | |||||
Proceeds from sale of short-term investments | 20,270 | 459 | |||||
Proceeds from maturity of short-term investments | 48,401 | — | |||||
Net cash used in investing activities | (79,760 | ) | (2,797 | ) | |||
Financing activities | |||||||
Net proceeds from stock option exercises and ESPP | 1,013 | 781 | |||||
Purchase of common stock for RSU vesting | (502 | ) | — | ||||
Net cash provided by financing activities | 511 | 781 | |||||
Net (decrease) increase in cash and cash equivalents | (66,135 | ) | 5,563 | ||||
Cash and cash equivalents at beginning of period | 97,428 | 160,203 | |||||
Cash and cash equivalents at end of period | $ | 31,293 | $ | 165,766 |
Supplemental disclosure of cash flow information | |||||||
Interest paid | $ | 919 | $ | 903 | |||
Taxes paid | 1 | 11 | |||||
Supplemental schedule of non-cash activity | |||||||
Stock issued for acquisition, net of issuance cost | (77,615 | ) | — | ||||
Accrued inventory purchases | 600 | 2,402 | |||||
Unrealized gain (loss) on AFS investments | (1,834 | ) | 4,614 |
As of December 31, 2015 | |||||||||||
As Reported | Adjustments | As Restated | |||||||||
Deferred income taxes | $ | 216,564 | $ | (27,481 | ) | $ | 189,083 | ||||
Total assets(1) | 530,542 | (27,481 | ) | 503,061 | |||||||
2019 convertible senior notes, net - current | — | 201,985 | 201,985 | ||||||||
Total current liabilities | 20,836 | 201,985 | 222,821 | ||||||||
2019 convertible senior notes, net - long term(1) | 201,985 | (201,985 | ) | — | |||||||
Equity component of currently redeemable convertible notes (Note 5) | — | 39,628 | 39,628 | ||||||||
Additional paid-in capital | 701,478 | (39,628 | ) | 661,850 | |||||||
Accumulated deficit | (402,010 | ) | (27,481 | ) | (429,491 | ) | |||||
Total stockholders' equity | 304,391 | (67,109 | ) | 237,282 | |||||||
Total liabilities and stockholders' equity(1) | 530,542 | (27,481 | ) | 503,061 | |||||||
(1) $3.4 million of unamortized issuance cost was reclassified to debt discount in the concurrently filed 2015 10-K/A form that it is filed after the Company's retrospective adoption of ASU 2015-03, Interest-Imputation of Interest: Simplifying the Presentation of Debt Issuance Costs in Q1 2016. |
As of March 31, 2016 | ||||||||||
As Reported | Adjustments | As Restated | ||||||||
Deferred income taxes | $ | 157,258 | (27,481 | ) | $ | 129,777 | ||||
Total assets | 613,438 | (27,481 | ) | 585,957 | ||||||
Accumulated deficit | (395,402 | ) | (27,481 | ) | (422,883 | ) | ||||
Total stockholders' equity | 392,077 | (27,481 | ) | 364,596 | ||||||
Total liabilities and stockholders' equity | 613,438 | (27,481 | ) | 585,957 |
Three months ended | |||||||
March 31, | |||||||
2016 | 2015 | ||||||
Net income from continuing operations | $ | 5,877 | $ | 754 | |||
Net income from discontinued operations | 731 | — | |||||
Net income | $ | 6,608 | $ | 754 | |||
Shares used to compute basic income per share | 20,707,926 | 19,611,881 | |||||
Dilutive potential common shares: | |||||||
Restricted stock | 66,736 | 61,538 | |||||
Stock options | 759,581 | 957,369 | |||||
0.75% Convertible Senior Notes, Due 2019 | 749,736 | — | |||||
Shares used to compute diluted income per share | 22,283,979 | 20,630,788 | |||||
Basic per share amounts: | |||||||
Income from continuing operations | $ | 0.28 | $ | 0.04 | |||
Income from discontinued operations | 0.04 | — | |||||
Basic net income per share | $ | 0.32 | $ | 0.04 | |||
Diluted per share amounts: | |||||||
Income from continuing operations | $ | 0.26 | $ | 0.04 | |||
Income from discontinued operations | 0.03 | — | |||||
Diluted net income per share | $ | 0.30 | $ | 0.04 |
Amortized cost | Gross unrealized gains | Gross unrealized losses | Estimated fair value | ||||||||||||
March 31, 2016 | |||||||||||||||
Short-term investments | |||||||||||||||
Bank deposits | $ | 42,376 | $ | 87 | $ | — | $ | 42,463 | |||||||
Corporate bonds | 24,268 | 84 | (2 | ) | 24,350 | ||||||||||
Commercial paper | 8,401 | 2 | — | 8,403 | |||||||||||
Asset backed securities | 2,067 | 1 | (1 | ) | 2,067 | ||||||||||
Corporate equity securities | 1,811 | 2,814 | — | 4,625 | |||||||||||
$ | 78,923 | $ | 2,988 | $ | (3 | ) | $ | 81,908 | |||||||
December 31, 2015 | |||||||||||||||
Short-term investments | |||||||||||||||
Bank deposits | $ | 43,043 | $ | — | $ | (4 | ) | $ | 43,039 | ||||||
Corporate bonds | 41,238 | $ | — | (35 | ) | 41,203 | |||||||||
Commercial paper | 1,747 | $ | — | — | 1,747 | ||||||||||
Asset backed securities | 10,020 | $ | — | (5 | ) | 10,015 | |||||||||
Corporate equity securities | 1,843 | $ | 4,944 | — | 6,787 | ||||||||||
$ | 97,891 | $ | 4,944 | $ | (44 | ) | $ | 102,791 |
March 31, | December 31, | ||||||
2016 | 2015 | ||||||
Indefinite lived intangible assets | |||||||
Acquired IPR&D | $ | 12,556 | $ | 12,556 | |||
Goodwill | 72,997 | 12,238 | |||||
Definite lived intangible assets | |||||||
Complete technology | 182,267 | 15,267 | |||||
Less: Accumulated amortization | (5,883 | ) | (3,762 | ) | |||
Trade name | 2,642 | 2,642 | |||||
Less: Accumulated amortization | (685 | ) | (652 | ) | |||
Customer relationships | 29,600 | 29,600 | |||||
Less: Accumulated amortization | (7,674 | ) | (7,304 | ) | |||
Total goodwill and other identifiable intangible assets, net | $ | 285,820 | $ | 60,585 |
March 31, | December 31, | ||||||
2016 | 2015 | ||||||
Lab and office equipment | $ | 2,482 | $ | 2,248 | |||
Leasehold improvements | 273 | 273 | |||||
Computer equipment and software | 636 | 632 | |||||
3,391 | 3,153 | ||||||
Less accumulated depreciation and amortization | (2,824 | ) | (2,781 | ) | |||
Total property and equipment, net | $ | 567 | $ | 372 |
March 31, | December 31, | ||||||
2016 | 2015 | ||||||
Prepaid expenses | $ | 1,087 | $ | 1,177 | |||
Other receivables | 475 | 731 | |||||
Total other current assets | $ | 1,562 | $ | 1,908 |
March 31, | December 31, | ||||||
2016 | 2015 | ||||||
Compensation | $ | 854 | $ | 1,711 | |||
Professional fees | 754 | 726 | |||||
Amounts owed to former licensees | 695 | 915 | |||||
Royalties owed to third parties | 937 | 823 | |||||
Other | 429 | 1,222 | |||||
Total accrued liabilities | $ | 3,669 | $ | 5,397 |
March 31, | December 31, | ||||||
2016 | 2015 | ||||||
Deposits | $ | 298 | $ | 268 | |||
Deferred rent | 107 | — | |||||
Other | 41 | 29 | |||||
Total other long-term liabilities | $ | 446 | $ | 297 |
Three months ended | ||||||||
March 31, | ||||||||
2016 | 2015 | |||||||
Stock-based compensation expense as a component of: | ||||||||
Research and development expenses | $ | 1,585 | $ | 920 | ||||
General and administrative expenses | 2,533 | 1,994 | ||||||
$ | 4,118 | $ | 2,914 |
Three months ended | ||||
March 31, | ||||
2016 | 2015 | |||
Risk-free interest rate | 1.5% | 1.8% | ||
Dividend yield | — | — | ||
Expected volatility | 50% | 58% | ||
Expected term | 6.6 | 6.6 | ||
Forfeiture rate | 5.0% | 8.5% |
Cash consideration | $ | 96,359 | |
Total share consideration: | |||
Actual number of shares issued | 793 | ||
Multiplied by: Ligand closing share price on January 8, 2016 | $ | 97.92 | |
Total share consideration | 77,658 | ||
Total consideration | $ | 174,017 |
Cash and cash equivalents | $ | 3,504 | |
Accounts receivable | 5 | ||
Income tax receivable | 140 | ||
Prepaid expenses and other current assets | 2 | ||
Deferred tax liabilities, net | (56,114 | ) | |
Intangible asset with finite life - core technology | 167,000 | ||
Liabilities assumed | (1,279 | ) | |
Goodwill | 60,759 | ||
Total consideration | $ | 174,017 |
March 31, | March 31, | |||||
2016 | 2015 | |||||
Revenue | $ | 32,124 | $ | 17,152 | ||
Net income | $ | 8,877 | $ | (474 | ) | |
Basic earnings per share: | $ | 0.43 | $ | (0.02 | ) | |
Diluted earnings per share: | $ | 0.40 | $ | (0.02 | ) |
Fair Value Measurements at Reporting Date Using | |||||||||||||||
Quoted Prices in Active Markets for Identical Assets | Significant Other Observable Inputs | Significant Unobservable Inputs | |||||||||||||
Total | (Level 1) | (Level 2) | (Level 3) | ||||||||||||
Assets: | |||||||||||||||
Cash equivalents (1) | $ | 5,316 | $ | — | $ | 5,316 | $ | — | |||||||
Short-term investments (2) | 81,908 | 4,625 | 77,283 | — | |||||||||||
Note receivable Viking (3) | 4,767 | — | — | 4,767 | |||||||||||
Total assets | $ | 91,991 | $ | 4,625 | $ | 82,599 | $ | 4,767 | |||||||
Liabilities: | |||||||||||||||
Current contingent liabilities-CyDex (4) | $ | 5,285 | $ | — | $ | — | $ | 5,285 | |||||||
Long-term contingent liabilities-CyDex (4) | 1,578 | — | — | 1,578 | |||||||||||
Long-term contingent liabilities-Metabasis (5) | 2,444 | — | 2,444 | — | |||||||||||
Liability for amounts owed to former licensees(6) | 534 | 534 | — | — | |||||||||||
Total liabilities | $ | 9,841 | $ | 534 | $ | 2,444 | $ | 6,863 |
Fair Value Measurements at Reporting Date Using | |||||||||||||||
Quoted Prices in Active Markets for Identical Assets | Significant Other Observable Inputs * | Significant Unobservable Inputs | |||||||||||||
Total | (Level 1) | (Level 2) | (Level 3) | ||||||||||||
Assets: | |||||||||||||||
Cash equivalents (1) | $ | 3,015 | $ | — | $ | 3,015 | $ | — | |||||||
Short-term investments (2) | 92,775 | 6,786 | 85,989 | — | |||||||||||
Viking note receivable (3) | 4,782 | — | — | 4,782 | |||||||||||
Total assets | $ | 100,572 | $ | 6,786 | $ | 89,004 | $ | 4,782 | |||||||
Liabilities: | |||||||||||||||
Current contingent liabilities-CyDex (4) | $ | 7,812 | $ | — | $ | — | $ | 7,812 | |||||||
Current contingent liabilities-Metabasis (5) | $ | 2,602 | — | 2,602 | — | ||||||||||
Long-term contingent liabilities-Metabasis (5) | 1,355 | — | 1,355 | — | |||||||||||
Long-term contingent liabilities-CyDex (4) | 1,678 | — | — | 1,678 | |||||||||||
Liability for amounts owed to former licensees (6) | 794 | 794 | — | — | |||||||||||
Total liabilities | $ | 14,241 | $ | 794 | $ | 3,957 | $ | 9,490 |
(1) | Highly liquid investments with maturities less than 90 days from the purchase date are recorded as cash equivalents that are classified as Level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market. |
(2) | Investments in equity securities, which the Company received as a result of event-based and upfront payments from licensees, are classified as level 1 as the fair value is determined using quoted market prices in active markets for the same securities. Short-term investments in marketable securities with maturities greater than 90 days are classified as level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or |
(3) | The fair value of the convertible note receivable from Viking was determined using a probability weighted option pricing model using a lattice methodology. The fair value is subjective and is affected by certain significant input to the valuation model such as the estimated volatility of the common stock, which was estimated to be 50% at March 31, 2016. Changes in these assumptions may materially affect the fair value estimate. |
(4) | The fair value of the liabilities for CyDex contingent liabilities were determined based on the income approach using a Monte Carlo analysis. The fair value is subjective and is affected by changes in inputs to the valuation model including management’s assumptions regarding revenue volatility, probability of commercialization of products, estimates of timing and probability of achievement of certain revenue thresholds and developmental and regulatory milestones which may be achieved and affect amounts owed to former license holders and CVR holders. Changes in these assumptions can materially affect the fair value estimate. |
(5) | The liability for CVRs for Metabasis are determined using quoted market prices in an inactive market for the underlying CVR. |
(6) | The liability for amounts owed to former licensees are determined using quoted market prices in active markets for the underlying investment received from a partner, a portion of which is owed to former licensees. |
(7) | The co-promote termination payments receivable represents a receivable for future payments to be made by Pfizer related to product sales and is recorded at its fair value. The receivable and liability will remain equal. The fair value is determined based on a valuation model using an income approach. |
March 31, 2016 | December 31, 2015 | ||
Range of annual revenue subject to revenue sharing (1) | $23.5 million | $22.5 million | |
Revenue volatility | 25% | 25% | |
Average probability of commercialization | 78% | 73% | |
Sales beta | 0.30 | 0.40 | |
Credit rating | BB | BB | |
Equity risk premium | 6% | 6% |
(1) | Revenue subject to revenue sharing represent management’s estimate of the range of total annual revenue subject to revenue sharing (i.e. annual revenues in excess of $15 million) through December 31, 2016, which is the term of the CVR agreement. |
Assets: | |||
Fair value of level 3 financial instrument assets as of December 31, 2015 | $ | 4,782 | |
Viking note receivable fair market value adjustment | (15 | ) | |
Fair value of level 3 financial instrument assets as of March 31, 2016 | $ | 4,767 | |
Liabilities: | |||
Fair value of level 3 financial instrument liabilities as of December 31, 2015 | $ | 9,490 | |
Payments to CVR and other former license holders | (2,828 | ) | |
Fair value adjustments to contingent liabilities | 201 | ||
Fair value of level 3 financial instrument liabilities as of March 31, 2016 | $ | 6,863 |
Operating lease obligations: | Lease Termination Date | Less than 1 year | 1-2 years | 3-4 years | Thereafter | Total | ||||||||||||
Corporate headquarters- La Jolla, CA | June 2019 | $ | 704 | $ | 1,465 | $ | 187 | $ | — | $ | 2,356 | |||||||
Corporate headquarters-San Diego, CA | April 2023 | 52 | 261 | 277 | 306 | 896 | ||||||||||||
Bioscience and Technology Business Center- Lawrence, KS | December 2017 | 54 | 41 | — | — | 95 | ||||||||||||
Vacated office and research facility- Cranbury, NJ | August 2016 | 1,089 | — | — | — | 1,089 | ||||||||||||
Total operating lease obligations | $ | 1,899 | $ | 1,767 | $ | 464 | $ | 306 | $ | 4,436 | ||||||||
Sublease payments expected to be received: | ||||||||||||||||||
Corporate headquarters- La Jolla, CA | June 2019 | $ | 443 | $ | 920 | $ | 116 | $ | — | $ | 1,479 | |||||||
Office and research facility- Cranbury, NJ | August 2016 | 88 | — | — | — | 88 | ||||||||||||
Net operating lease obligations | $ | 1,368 | $ | 847 | $ | 348 | $ | 306 | $ | 2,869 |
March 31, 2016 | December 31, 2015 | ||||||
2019 Convertible Senior Notes | |||||||
Principal amount outstanding | $ | 245,000 | $ | 245,000 | |||
Unamortized discount | (37,169 | ) | (39,628 | ) | |||
Net carrying amount | 207,831 | 205,372 | |||||
Less: Unamortized deferred financing costs | 3,178 | 3,387 | |||||
Total notes payable | $ | 204,653 | $ | 201,985 |
Stock Options | Restricted Stock Award | ||||||||||||
Shares | Weighted- Average Exercise Price | Shares | Weighted- Average Grant Date Fair Value | ||||||||||
Balance as of December 31, 2015 | 1,683,341 | $ | 34.23 | 130,749 | $ | 60.36 | |||||||
Granted | 241,015 | 88.84 | 229,847 | 94.76 | |||||||||
Exercised | (44,029 | ) | 23.00 | (34,649 | ) | 52.18 | |||||||
Balance as of March 31, 2016 | 1,880,327 | 41.50 | 325,947 | 72.88 |
ITEM 2. | Management's Discussion and Analysis of Financial Condition and Results of Operations |
• | In May 2016, Ligand acquired the economic rights to multiple programs owned by CorMatrix. Ligand paid $17.5 million and in return will receive a portion of revenue (synthetic royalty) from CorMatrix’s existing marketed products and will have the right to receive future synthetic royalties from potential future products. CorMatrix’s products are medical devices that are designed to permit the development and regrowth of human tissue. This transaction will be immediately accretive to Ligand and represents Ligand’s entry into the field of medical devices. |
• | In January 2016, Ligand acquired OMT, Inc. and its OmniAb™ platform for consideration valued at the time of the acquisition at approximately $178 million. OmniAb license agreements existing at the time of acquisition initially added 16 shots on goal, with the potential for additional compounds to be generated from these partnerships. Partners at the time of acquisition included Amgen, Celgene, Genmab, Janssen, Merck KGaA, Pfizer, Seattle Genetics, Five Prime, Symphogen and various other biotechnology and pharmaceutical companies. |
• | The European Commission approved Revolade® (eltrombopag), a Novartis product, for the treatment of pediatric (age 1 and above) chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients who are refractory to other treatments (e.g., corticosteroids, immunoglobulins). The approval includes the use of tablets as well as a new oral suspension formulation of Revolade®, which is designed for younger children who may not be able to swallow tablets. |
• | On January 21, 2016, Amgen announced that FDA approved Kyprolis® (carfilzomib) in combination with dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy. The FDA also approved Kyprolis® as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy, converting to full approval the initial accelerated approval Kyprolis® received in July 2012 as a single agent. |
• | On January 28, 2016, Amgen announced Health Canada approval of Kyprolis® (carfilzomib) in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three lines of therapy. |
• | Spectrum Pharmaceuticals received FDA approval of EVOMELA™ (melphalan) for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma, and for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. |
• | Spectrum Pharmaceuticals announced that the FDA granted seven years of Orphan Drug Exclusivity for EVOMELA™ for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma. |
• | Duavive® received EU pricing and was launched in Italy by Merck Sharp & Dohme, under license from Pfizer. |
• | Alvogen Inc. received approval from the FDA for Captisol-enabled IV voriconazole. |
• | Zydus Cadila announced the launch of Vivitra™, a biosimilar of trastuzumab, in India. Ligand gained rights to royalties on sales of Vivitra in the March 2013 Selexis royalty acquisition. |
• | Lundbeck announced the FDA accepted the resubmission of the NDA for IV carbamazepine. An action letter is anticipated before the end of 2016. |
• | Retrophin announced completion of enrollment in the Phase 2 DUET study of Sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS). The DUET study exceeded its enrollment target of 100 patients, and top-line results are expected in the third quarter of 2016. |
• | Sage Therapeutics presented data that expanded scientific, clinical and burden-of-illness data for SAGE-547 at the 68th American Academy of Neurology Annual Meeting. |
• | Coherus BioSciences and Baxalta announced that CHS-0214, a proposed biosimilar of Enbrel® (etanercept) to which Ligand gained royalty rights in the March 2013 Selexis royalty acquisition, met its primary endpoint in a confirmatory, double-blind, randomized, controlled, two-part clinical study. This ongoing study is evaluating the efficacy and safety of CHS-0214 compared with Enbrel® in patients with moderate-to-severe rheumatoid arthritis that is inadequately controlled with methotrexate. |
• | Viking Therapeutics highlighted positive data from a Phase 1b trial of VK2809 (TR Beta) in subjects with mild hypercholesterolemia at the 65th Annual Scientific Session and Expo of the American College of Cardiology. |
• | Merrimack Pharmaceuticals presented data on MM-302, MM-141 and MM-151 at the 2016 American Association for Cancer Research Annual Meeting. |
• | Opthea Limited announced that the primary objective of safety in the dose-escalation phase of its ongoing first-in-human clinical trial of OPT-302, a novel VEGF-C/D 'Trap' therapy for wet age-related macular degeneration, had been met. |
• | Marinus Pharmaceuticals announced that the FDA granted Orphan Drug designation for ganaxolone IV for the treatment of status epilepticus. A Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of ganaxolone IV is expected to initiate in the first half of 2016. |
• | Marinus Pharmaceuticals presented preclinical data of ganaxolone IV, which showed robust activity in the model. The data were presented during an oral and poster presentations at the 68th American Academy of Neurology Annual Meeting. |
• | AVEO Oncology announced granting CANbridge Life Sciences worldwide rights, excluding the United States, Canada and Mexico, to AV-203, AVEO’s clinical-stage ErbB3 (HER3) inhibitory antibody candidate. |
• | The journal Nature published an article highlighting the efficacy of Gilead’s GS-5734 against the Ebola virus in rhesus monkeys. |
• | Ligand announced a worldwide license agreement with Emergent BioSolutions that allows Emergent to use the OmniAb platform to discover fully human mono- and bispecific antibodies. Ligand is eligible to receive annual access payments, fees on patent filings, milestone payments and royalties on future net sales of any antibodies discovered under the license. |
• | Ligand announced a worldwide license agreement with Tizona Therapeutics that allows Tizona to use the OmniAb platform to discover fully human mono- and bispecific antibodies. Ligand is eligible to receive annual access payments, fees on patent filings, milestone payments and royalties on future net sales of any antibodies discovered under the license. |
• | Ligand announced a worldwide license agreement with ABBA Therapeutics that allows ABBA to use the OmniAb platform to discover fully human mono- and bispecific antibodies. Ligand is eligible to receive milestone payments and royalties on future net sales of any antibodies discovered under the license. |
• | Ligand entered into a Clinical Use Agreement with XTL Biopharmaceuticals to supply Captisol for use in the formulation of its lead drug, hCDR1, for the treatment of systemic lupus erythematosus. Under the terms of the agreement, Ligand is eligible to receive milestones and revenue from clinical Captisol sales. |
• | Ligand scientists gave an oral presentation on GRA at ENDO 2016 and presented a poster at the Levine-Riggs Diabetes Research Symposium, which highlighted data from the Phase 1b trial demonstrating that GRA significantly reduced fasting and post-prandial glucose in subjects with type 2 diabetes. |
ITEM 3. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK |
ITEM 4. | CONTROLS AND PROCEDURES |
PART II. | OTHER INFORMATION |
ITEM 1A. | RISK FACTORS |
ITEM 6. | EXHIBITS |
Date: | November 14, 2016 | By: | /s/ Matthew Korenberg | |
Matthew Korenberg | ||||
Vice President, Finance and Chief Financial Officer | ||||
Duly Authorized Officer and Principal Financial Officer |
Exhibit Number | Description |
10.1 | Second Amendment to the Loan and Security Agreement, dated January 22, 2016 by and among the Company and Viking Therapeutics, Inc. |
31.1 | Certification by Principal Executive Officer, Pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
31.2 | Certification by Principal Financial Officer, Pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
32.1 | Certifications by Principal Executive Officer and Principal Financial Officer, Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
101.INS | XBRL Instance Document |
101.SCH | XBRL Taxonomy Extension Schema Document |
101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document |
101.DEF | XBRL Taxonomy Extension Definition Linkbase Document |
101.LAB | XBRL Taxonomy Extension Label Linkbase Document |
101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document |
1. | I have reviewed this Quarterly Report on Form 10-Q/A of Ligand Pharmaceuticals Incorporated; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a) | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b) | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c) | evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d) | disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. | The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
a) | all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
b) | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
/s/ John L. Higgins |
John L. Higgins |
Chief Executive Officer |
(Principal Executive Officer) |
1. | I have reviewed this Quarterly Report on Form 10-Q/A of Ligand Pharmaceuticals Incorporated; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a) | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b) | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c) | evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d) | disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. | The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
a) | all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
b) | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
/s/ Matthew Korenberg |
Matthew Korenberg |
Vice President, Finance and Chief Financial Officer |
(Principal Financial Officer) |
(1) | The Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and |
(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. | |||
Date: | November 14, 2016 | /s/ John L. Higgins | ||
John L. Higgins Chief Executive Officer (Principal Executive Officer) |
(1) | The Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and |
(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. | |||
Date: | November 14, 2016 | /s/ Matthew Korenberg | ||
Matthew Korenberg Vice President, Finance and Chief Financial Officer (Principal Financial Officer) |
Document and Entity Information - shares |
3 Months Ended | |
---|---|---|
Mar. 31, 2016 |
May 01, 2016 |
|
Document and Entity Information [Abstract] | ||
Entity Registrant Name | LIGAND PHARMACEUTICALS INC | |
Entity Central Index Key | 0000886163 | |
Document Type | 10-Q | |
Document Period End Date | Mar. 31, 2016 | |
Amendment Flag | false | |
Document Fiscal Year Focus | 2016 | |
Document Fiscal Period Focus | Q1 | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Accelerated Filer | |
Entity Common Stock, Shares Outstanding | 20,822,444 |
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares |
Mar. 31, 2016 |
Dec. 31, 2015 |
---|---|---|
Statement of Financial Position [Abstract] | ||
Common stock, par value (USD per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 33,333,333 | 33,333,333 |
Common stock, shares issued | 20,815,636 | 19,949,012 |
Common stock, shares outstanding | 20,815,636 | 19,949,012 |
Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2016 |
Mar. 31, 2015 |
|
Statement of Comprehensive Income [Abstract] | ||
Net income: | $ 6,608 | $ 754 |
Unrealized net (loss) gain on available-for-sale securities, net of tax | (1,098) | 4,614 |
Less: Reclassification of net realized (gains) losses included in net income, net of tax | (236) | (234) |
Comprehensive income (loss) | $ 5,274 | $ 5,134 |
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2016 |
Mar. 31, 2015 |
|
Operating activities | ||
Net income including noncontrolling interests | $ 6,608 | $ (89) |
Less: gain from discontinued operations | 731 | 0 |
Income (loss) from operations | 5,877 | (89) |
Adjustments to reconcile net income including noncontrolling interests to net cash provided by operating activities: | ||
Non-cash change in estimated fair value of contingent liabilities | 1,306 | 3 |
Realized gain on sale of short-term investment | (406) | 447 |
Depreciation and amortization | 2,575 | 650 |
Amortization of discount on investments, net | 320 | 0 |
Amortization of debt discount and issuance fees | 2,668 | 2,509 |
Stock-based compensation | 4,118 | 2,914 |
Deferred income taxes | 4,101 | 6 |
Accretion of note payable | 0 | 14 |
Change in fair value of the convertible debt receivable from Viking | 15 | 0 |
Loss on equity investment in Viking Therapeutics, Inc. | 1,605 | 0 |
Other | (1) | |
Changes in operating assets and liabilities: | ||
Accounts receivable | (5,604) | 5,211 |
Inventory | 853 | (150) |
Other current assets | 16 | 445 |
Other long-term assets | (41) | (291) |
Accounts payable and accrued liabilities | (4,302) | (4,667) |
Restricted investments | 0 | 661 |
Deferred revenue | 13 | (83) |
Net cash provided by operating activities | 13,114 | 7,579 |
Investing activities | ||
Payments to CVR holders and other contingency payments | (5,446) | (3,247) |
Purchases of property and equipment | (238) | (10) |
Cash paid for acquisition, net of cash acquired | (92,855) | 0 |
Purchase of short-term investments | (49,892) | 0 |
Proceeds from sale of property and equipment | 0 | 1 |
Proceeds from sale of short-term investments | 20,270 | 459 |
Proceeds from maturity of short-term investments | 48,401 | 0 |
Net cash used in investing activities | (79,760) | (2,797) |
Financing activities | ||
Net proceeds from stock option exercises and ESPP | 1,013 | 781 |
Purchase of common stock for RSU vesting | (502) | 0 |
Net cash provided by financing activities | 511 | 781 |
Net (decrease) increase in cash and cash equivalents | (66,135) | 5,563 |
Cash and cash equivalents at beginning of period | 97,428 | 160,203 |
Cash and cash equivalents at end of period | 31,293 | 165,766 |
Supplemental disclosure of cash flow information | ||
Interest paid | 919 | 903 |
Taxes paid | 1 | 11 |
Supplemental schedule of non-cash activity | ||
Stock issued for acquisition | (77,615) | 0 |
Accrued Inventory Purchases | 600 | 2,402 |
Unrealized gain on AFS investments | $ (1,834) | $ 4,614 |
Significant Accounting Policies |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Significant Accounting Policies | Significant Accounting Principles Business Ligand is a biopharmaceutical company with a business model that is based upon the concept of developing or acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure. We operate in one business segment: development and licensing biopharmaceutical assets. Principles of Consolidation The accompanying consolidated financial statements include Ligand and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. Basis of Presentation The Company’s accompanying unaudited condensed consolidated financial statements as of March 31, 2016 and for the three months ended March 31, 2016 and 2015 have been prepared in accordance with GAAP for interim financial information. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position and results of operations of the Company and its subsidiaries, have been included. Operating results for the three months ended March 31, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. These financial statements should be read in conjunction with the consolidated financial statements and notes therein included in the Company’s annual report on Form 10-K/A for the year ended December 31, 2015 filed on November 14, 2016. Restatement The Company has restated its financial statements for the year ended December 31, 2015 to correct errors relating to the Company's net operating loss (NOL) carryforward benefits in the United States which resulted in an overstatement of deferred tax assets (DTA) at December 31, 2015 and March 31, 2016. In connection with three acquisitions that were completed prior to February 2010, the Company recognized DTAs for a portion of the NOLs, which included capitalized research and development expenses, obtained from the acquired businesses. From the time of the acquisitions until September 2015, there was a valuation allowance against all of the Company’s NOLs, including those obtained from the entities acquired. In September 2015, the Company concluded that it was more likely than not that a substantial portion of it deferred tax assets would be realized through future taxable income. As a result, the Company released the majority of its DTA valuation allowance in full, including $27.5 million related to NOLs recognized as part of the businesses acquired prior to February of 2010. During the quarter ended September 30, 2016, the Company concluded that for accounting purposes the approximately $27.5 million of DTAs that were obtained upon acquiring the businesses prior to February of 2010 did not meet the more likely-than-not criterion for recognition in 2015 and that the related valuation allowance should not have been reversed. As a result, the Company's income tax benefit and net income for the year ended December 31, 2015 were overstated by $27.5 million each as were the Company's DTAs at March 31, 2016. Based on the materiality guidelines contained in SEC Staff Accounting Bulletin No. 99, Materiality, and SEC Staff Accounting Bulletin No. 108, Considering the Effects of Prior Year Misstatements in Current Year Financial Statements, the Company believes that the income tax adjustment is material to its financial statements for periods subsequent to and including the year ended December 31, 2015. Accordingly, the Company determined that it would restate prior period financial statements and amend its previously filed affected filings, including its March 31, 2016 report on Form 10-Q and December 31, 2015 report on Form 10-K. The Company also recorded adjustments as part of this restatement related to the classification of our 2019 Convertible Senior Notes. As of December 31, 2015, the Company's last reported sale price exceeded the 130% threshold described in Note 6 - "Financing Arrangements" and accordingly the 2019 Convertible Senior Notes have been reclassified as a current liability as of December 31, 2015. As a result, the related unamortized discount of $39.6 million previously classified within stockholder's equity was reclassified as temporary equity component of currently redeemable convertible notes on our Condensed Consolidated Balance Sheet. The effects of these prior period corrections are as follows:
Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires the use of estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. Actual results may differ from those estimates. Reclassifications Certain reclassifications have been made to the previously issued balance sheet and statement of operations for the three months ended March 31, 2015 for comparability purposes. These reclassifications had no effect on the reported net income, stockholders' equity, and operating cash flows as previously reported. Income Per Share Basic income per share is calculated by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted income per share is computed by dividing net income by the weighted-average number of common shares and common stock equivalents of all dilutive securities calculated using the treasury stock method and the if-converted method. The total number of potentially dilutive securities including stock options and warrants excluded from the computation of diluted income per share because their inclusion would have been anti-dilutive was 3.5 million and 4.5 million, as of March 31, 2016 and 2015, respectively. The following table presents the computation of basic and diluted net income per share for the periods indicated (in thousands, except per share amounts):
Cash Equivalents Cash equivalents consist of all investments with maturities of three months or less from the date of acquisition. Short-term Investments Short-term investments primarily consist of investments in debt securities that have effective maturities greater than three months and less than twelve months from the date of acquisition. The Company classifies its short-term investments as "available-for-sale". Such investments are carried at fair value, with unrealized gains and losses included in the statement of comprehensive income (loss). The Company determines the cost of investments based on the specific identification method. Restricted Investments Restricted investments consist of certificates of deposit held with a financial institution as collateral under a facility lease and third-party service provider arrangements. The following table summarizes the various investment categories at March 31, 2016 and December 31, 2015 (in thousands):
Inventory Inventory, which consists of finished goods, is stated at the lower of cost or market value. The Company determines cost using the first-in, first-out method. Inventory levels are analyzed periodically and written down to its net realizable value if it has become obsolete, has a cost basis in excess of its expected net realizable value or is in excess of expected requirements. There were no write downs related to obsolete inventory recorded for the three months ended March 31, 2016 and 2015. Goodwill and Other Identifiable Intangible Assets Goodwill and other identifiable intangible assets consist of the following (in thousands):
As Discussed in Note 2-Business Combination, on January 8, 2016, the Company completed its acquisition of OMT. As a result of the transaction, the Company recorded $167.0 million of intangibles with definite lives and goodwill of $60.8 million. Amortization of definite-lived intangible assets is computed using the straight-line method over the estimated useful life of the asset of 20 years. Amortization expense of $2.5 million was recognized for the three months ended March 31, 2016 and amortization expense of $0.6 million was recognized for the three months ended March 31, 2015. Estimated amortization expense for the year ending December 31, 2016 is $10.6 million and estimated amortization expense for the years ended December 31, 2017 through 2020 is $10.7 million per year. For each of the three months ended March 31, 2016 and 2015, there was no impairment of IPR&D or goodwill. Commercial License Rights Commercial license rights represent a portfolio of future milestone and royalty payment rights acquired from Selexis in April 2013 and April 2015. Individual commercial license rights acquired under the agreement are carried at allocated cost and approximate fair value. The carrying value of the license rights will be reduced on a pro-rata basis as revenue is realized over the term of the agreement. Declines in the fair value of individual license rights below their carrying value that are deemed to be other than temporary are reflected in earnings in the period such determination is made. As of March 31, 2016, management does not believe there have been any events or circumstances indicating that the carrying amount of its commercial license rights may not be recoverable. Property and Equipment Property and equipment is stated at cost and consists of the following (in thousands):
Depreciation of equipment is computed using the straight-line method over the estimated useful lives of the assets, which range from three to ten years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful lives or the related lease term. Depreciation expense of $0.1 million was recognized for each of the three months ended March 31, 2016 and 2015, respectively, which is included in operating expenses. Other Current Assets Other current assets consist of the following (in thousands):
Accrued Liabilities Accrued liabilities consist of the following (in thousands):
Other Long-Term Liabilities Other long-term liabilities consist of the following (in thousands):
Contingent Liabilities In connection with the Company’s acquisition of CyDex in January 2011, the Company recorded a contingent liability, for amounts potentially due to holders of the CyDex CVRs and former license holders. The liability is periodically assessed based on events and circumstances related to the underlying milestones, royalties and material sales. Any change in fair value is recorded in the Company’s consolidated statement of operations. The carrying amount of the liability may fluctuate significantly and actual amounts paid under the CVR agreements may be materially different than the carrying amount of the liability. The fair value of the liability at March 31, 2016 and December 31, 2015 was $6.9 million and $9.5 million, respectively. The Company recorded a fair-value adjustment to increase the liability by $0.2 million and $1.2 million for the three months ended March 31, 2016 and 2015, respectively. There was a revenue-sharing payment of $2.8 million and $3.2 million to CyDex CVR holders during the three months ended March 31, 2016 and 2015, respectively. In connection with the Company’s acquisition of Metabasis in January 2010, the Company issued to Metabasis stockholders four tradable CVRs, one CVR from each of four respective series of CVR, for each Metabasis share. The CVRs will entitle Metabasis stockholders to cash payments as frequently as every six months as cash is received by the Company from proceeds from the sale or partnering of any of the Metabasis drug development programs, among other triggering events. The fair values of the CVRs are remeasured at each reporting date through the term of the related agreement. Any change in fair value is recorded in the Company’s consolidated statement of operations. The carrying amount of the liability may fluctuate significantly based upon quoted market prices and actual amounts paid under the agreements may be materially different than the carrying amount of the liability. The fair value of the liability was estimated to be $2.4 million and $4.0 million as of March 31, 2016 and December 31, 2015, respectively. The Company recorded an increase in the liability for Metabasis-related CVRs of $1.1 million and an decrease of $1.2 million for the three months ended March 31, 2016 and 2015, respectively. The Company paid Metabasis CVR holders $2.6 million for the three months ended March 31, 2016. No payments were made to Metabasis CVR holders for the three months ended March 31, 2015. Revenue Recognition Royalties on sales of products commercialized by the Company’s partners are recognized in the quarter reported to Ligand by the respective partner. Generally, the Company receives royalty reports from its licensees approximately one quarter in arrears due to the fact that its agreements require partners to report product sales between 30 and 60 days after the end of the quarter. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured. Under this accounting policy, the royalty revenues reported are not based upon estimates and such royalty revenues are typically reported to the Company by its partners in the same period in which payment is received. Revenue from material sales of Captisol is recognized upon transfer of title, which normally passes upon shipment to the customer, provided all other revenue recognition criteria have been met. All product returns are subject to the Company's credit and exchange policy, approval by the Company and a 20% restocking fee. To date, product returns by customers have not been material to net material sales in any related period. The Company records revenue net of product returns, if any, and sales tax collected and remitted to government authorities during the period. The Company analyzes its revenue arrangements and other agreements to determine whether there are multiple elements that should be separated and accounted for individually or as a single unit of accounting. For multiple element contracts, arrangement consideration is allocated at the inception of the arrangement to all deliverables on the basis of relative selling price, using a hierarchy to determine selling price. Management first considers VSOE, then TPE and if neither VSOE nor TPE exist, the Company uses its best estimate of selling price. Many of the Company's revenue arrangements for Captisol involve a license agreement with the supply of manufactured Captisol product. Licenses may be granted to pharmaceutical companies for the use of Captisol product in the development of pharmaceutical compounds. The supply of the Captisol product may be for all phases of clinical trials and through commercial availability of the host drug or may be limited to certain phases of the clinical trial process. Management believes that the Company's licenses have stand-alone value at the outset of an arrangement because the customer obtains the right to use Captisol in its formulations without any additional input by the Company. Other nonrefundable, upfront license fees are recognized as revenue upon delivery of the license, if the license is determined to have standalone value that is not dependent on any future performance by the Company under the applicable collaboration agreement. Nonrefundable contingent event-based payments are recognized as revenue when the contingent event is met, which is usually the earlier of when payments are received or collections are assured, provided that it does not require future performance by the Company. The Company occasionally has sub-license obligations related to arrangements for which it receives license fees, milestones and royalties. The Company evaluates the determination of gross versus net reporting based on each individual agreement. Sales-based contingent payments from partners are accounted for similarly to royalties, with revenue recognized upon achievement of the sales targets assuming all other revenue recognition criteria for milestones are met. Revenue from development and regulatory milestones is recognized when earned, as evidenced by written acknowledgement from the collaborator, provided that (1) the milestone event is substantive, its achievability was not reasonably assured at the inception of the agreement, and the Company has no further performance obligations relating to that event, and (2) collectability is reasonably assured. If these criteria are not met, the milestone payment is recognized over the remaining period of the Company’s performance obligations under the arrangement. Revenue from research funding under our collaboration agreements is earned and recognized on a percentage-of completion basis as research hours are incurred in accordance with the provisions of each agreement. Stock-Based Compensation Stock-based compensation expense for awards to employees and non-employee directors is recognized on a straight-line basis over the vesting period until the last tranche vests. The following table summarizes stock-based compensation expense recorded as components of research and development expenses and general and administrative expenses for the periods indicated (in thousands):
The fair-value for options that were awarded to employees and directors was estimated at the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions:
Income Taxes Income taxes are accounted for under the liability method. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of differences between the tax basis of assets or liabilities and their carrying amounts in the consolidated financial statements. The Company provides a valuation allowance for deferred tax assets if it is more likely than not that these items will expire before we are able to realize their benefit. The Company calculates the valuation allowance in accordance with the authoritative guidance relating to income taxes under ASC 740, Income Taxes, which requires an assessment of both positive and negative evidence that is available regarding the reliability of these deferred tax assets, when measuring the need for a valuation allowance. Developing the provision for income taxes requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred tax assets and liabilities and, if necessary, any valuation allowances that may be required for deferred tax assets. The Company's judgments and tax strategies are subject to audit by various taxing authorities. While management believes the Company has provided adequately for its income tax liabilities in its consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the Company's consolidated financial condition and results of operations. Variable Interest Entities The Company identifies an entity as a VIE if either: (1) the entity does not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support, or (2) the entity's equity investors lack the essential characteristics of a controlling financial interest. The Company performs ongoing qualitative assessments of its VIEs to determine whether the Company has a controlling financial interest in any VIE and therefore is the primary beneficiary. If the Company is the primary beneficiary of a VIE, it consolidates the VIE under applicable accounting guidance. If the Company is no longer the primary of a VIE or the entity is no longer considered as a VIE as facts and circumstances changed, it deconsolidates the entity under the applicable accounting guidance. Beginning May 2015, the Company deconsolidated Viking, a previously reported VIE, and elected to record its investment in Viking under the equity method of accounting as Viking is no longer considered a VIE and the Company does not have voting control or other elements of control that would require consolidation. The investment is subsequently adjusted for the Company’s share of Viking's operating results, and if applicable, cash contributions and distributions, which is reported on a separate line in our condensed consolidated statement of operations called “Equity in net losses of Viking Therapeutics”. On the condensed consolidated balance sheet, the Company reports its investment in Viking on a separate line in the non-current assets section called “Investment in Viking Therapeutics”. See Note 3, Investment in Viking Therapeutics, for additional details. Convertible Debt In August 2014, the Company completed a $245.0 million offering of 2019 Convertible Senior Notes, which bear interest at 0.75%. The Company accounts for the 2019 Convertible Senior Notes by separating the liability and equity components of the instrument in a manner that reflects the Company's nonconvertible debt borrowing rate. As a result, the Company assigned a value to the debt component of the 2019 Convertible Senior Notes equal to the estimated fair value of similar debt instruments without the conversion feature, which resulted in the Company recording the debt instrument at a discount. The Company is amortizing the debt discount over the life of the 2019 Convertible Senior Notes as additional non-cash interest expense utilizing the effective interest method. Recent Accounting Pronouncements In May 2014, FASB issued ASU 2014-09, Revenue from Contracts with Customers. ASU 2014-09 is effective for annual periods beginning after December 15, 2016 and interim periods within those annual periods. The revenue standard’s core principle is built on the contract between a vendor and a customer for the provision of goods and services. It attempts to depict the exchange of rights and obligations between the parties in the pattern of revenue recognition based on the consideration to which the vendor is entitled. To accomplish this objective, the standard requires five basic steps: (1) identify the contract with the customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, (5) recognize revenue when (or as) the entity satisfies a performance obligation. Management is currently evaluating the effect the adoption of this standard will have on the Company's financial statements. In April 2015, FASB issued ASU 2015-03, Interest-Imputation of Interest: Simplifying the Presentation of Debt Issuance Costs. This update was issued to simplify the presentation for debt issuance costs. Upon adoption, such costs shall be presented on our consolidated balance sheets as a direct deduction from the carrying amount of the related debt liability and not as a deferred charge presented in Other assets on our consolidated balance sheets. This amendment will be effective for interim and annual periods beginning on January 1, 2016, and is required to be retrospectively adopted. During the three-month period ended March 31, 2016, management adopted the change in the presentation on our consolidated balance sheets accordingly (see Note 6 for details). In January 2016, the FASB issued ASU 2016-01 Recognition and Measurement of Financial Assets and Financial Liabilities that amends the accounting and disclosures of financial instruments, including a provision that requires equity investments (except for investments accounted for under the equity method of accounting) to be measured at fair value with changes in fair value recognized in current earnings. The new standard is effective for interim and annual periods beginning on January 1, 2018. We are currently evaluating the impact that this new standard will have on our consolidated financial statements. In February 2016, the FASB issued a new accounting standard that amends the guidance for the accounting and disclosure of leases. This new standard requires that lessees recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative information about their leasing arrangements. The new standard is effective for interim and annual periods beginning on January 1, 2019. We are currently evaluating the impact that this new standard will have on our consolidated financial statements. In March 2016, the FASB issued ASU 2016-09, Compensation – Stock Compensation, which identifies areas for simplification involving several aspects of accounting for stock-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, an option to recognize gross stock compensation expense with actual forfeitures recognized as they occur, as well as certain classifications on the statement of cash flows. ASU No. 2016-09 is effective for reporting periods beginning after December 31, 2016. Early adoption is permitted. We are currently assessing the potential impact that the adoption of ASU No. 2016-09 will have in our condensed consolidated financial statements. |
Business Combination |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Combinations [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Combination | Business Combination On January 8, 2016, the Company acquired substantially all of the assets and liabilities of OMT. OMT is a biotechnology company engaged in the genetic engineering of animals for the generation of human therapeutic antibodies through its OmniAb® technology, which currently offers three transgenic animal platforms for license, including OmniRat®, OmniMouse® and OmniFlic®. The transaction, which was accounted for as a business combination, added 16 partnered programs to the Company's portfolio and provides the Company with opportunities for further licensing and collaborations in the area. The aggregate acquisition consideration was $174.0 million, consisting of (in thousands):
The acquisition consideration is subject to certain customary post-closing adjustments up to 15 months from January 8, 2016, in accordance with the terms and subject to the conditions contained in the Merger Agreement between the Company and OMT. The acquisition consideration was preliminarily allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):
The fair value of the core technology, or OMT's OmniAb technology, was based on the discounted cash flow method that estimated the present value of a hypothetical royalty stream derived from the licensing of the OmniAb technology. These projected cash flows were discounted to present value using a discount rate of 15.5%. The fair value of the core technology is being amortized on a straight-line bases over the estimated useful life of 20 years. The excess of the acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $60.8 million was recorded as goodwill, which is not deductible for tax purposes and is primarily attributable to OMT’s revenue growth from combining the OMT and Ligand businesses and workforce, as well as the benefits of access to different markets and customers. The purchase price allocations were prepared on a preliminary basis and are subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed. Any measurement period adjustments to the OMT purchase price allocation will be made as soon as practicable but no later than one year from the date of acquisition. The following table presents supplemental pro forma information for the three months ended March 31, 2016 and March 31, 2015, as if the acquisition of OMT had occurred on January 1, 2015 (in thousands except for EPS):
The unaudited pro forma consolidated results include pro forma adjustments that assume the acquisition occurred on January 1, 2015. The primary adjustments include: (i) the $0.3 million share based compensation expenses related to the stock awards issued to the retained OMT employees after the acquisition, and (ii) additional intangible amortization expense of $0.2 million and $2.1 million was included in the quarter ended March 31, 2016 and 2015, respectively. The adjustments also include $2.5 million license revenue recognized by OMT from January 1, 2016 to the acquisition date. The unaudited pro forma consolidated results are not necessarily indicative of what our consolidated results of operations actually would have been had we completed the acquisition on January 1, 2015. In addition, the unaudited pro forma consolidated results do not purport to project the future results of operations of the combined company nor do they reflect the expected realization of any cost savings associated with the acquisition. |
Fair Value Measurements |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Measurements | Fair Value Measurements The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. The Company establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels are described below with level 1 having the highest level input that is significant to the measurement and level 3 having the lowest: Level 1 - Quoted prices in active markets; Level 2 - Inputs other than the quoted prices in active markets that are observable either directly or indirectly; and Level 3 - Unobservable inputs in which there is little or no market data, which require the Company to develop its own assumptions. The following table provides a summary of the carrying value of assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2016 (in thousands). There were no transfers between Level 1 and Level 2 securities during the three months ended March 31, 2016:
The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2015 (in thousands):
The following table represents significant unobservable inputs used in determining the fair value of contingent liabilities assumed in the acquisition of CyDex:
A reconciliation of the level 3 financial instruments as of March 31, 2016 is as follows (in thousands):
Other Fair Value Measurements 2019 Convertible Senior Notes In August 2014, the Company issued $245.0 million aggregate principal amount of its 2019 Convertible Senior Notes. The Company uses a quoted market rate in an inactive market, which is classified as a Level 2 input, to estimate the current fair value of its 2019 Convertible Senior Notes. The estimated fair value of the 2019 Senior Convertible Notes was $373.5 million as of March 31, 2016. The carrying value of the notes does not reflect the market rate. See Note 7 Financing Arrangements for additional information. Viking Therapeutics The Company records its investment in Viking under the equity method of accounting. The investment is subsequently adjusted for the Company’s share of Viking's operating results, and if applicable, cash contributions and distributions. See Note 3 Investment in Viking Therapeutics for additional information. The market value of the Company's investment in Viking was $6.8 million as of March 31, 2016. The carrying value of the investment in Viking does not reflect the market value. |
Investment in Viking Therapeutics, Inc. |
3 Months Ended |
---|---|
Mar. 31, 2016 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Investment in Viking Therapeutics, Inc. | Investment in Viking Therapeutics In 2014, the Company entered into a MLA with Viking to license the rights to five of the Company's programs to Viking. Under the terms of the MLA, no consideration was exchanged upon execution, but rather Viking agreed to issue shares of Viking common stock with an aggregate value of approximately $29.2 million upon consummation of Viking's IPO. As part of this transaction, the Company also extended a $2.5 million convertible loan to Viking under a LSA. As a result of these transactions, the Company determined it held a variable interest in Viking. The Company considered certain criteria in the accounting guidance for VIEs, and determined that Viking was a VIE and Ligand was the primary beneficiary of Viking. As a result, the Company consolidated Viking on its financial statements from May 2014 through May 2015, the effective date of Viking's IPO. The Company recorded 100% of the losses incurred as net loss attributable to noncontrolling interest because it was the primary beneficiary with no equity interest in the VIE. In May 2015, Viking completed the Viking IPO and issued the Company approximately 3.7 million shares of Viking common stock with an aggregate value of $29.2 million based on the IPO price of $8.00 per share. In connection with the Viking IPO, the Company purchased 1.1 million shares of Viking common stock for an aggregate price of $9.0 million at the initial public offering price. Upon completion of Viking’s IPO, the Company determined that Viking was no longer a VIE and the Company did not have any other element of control that would require consolidation of Viking. In May 2015, the Company deconsolidated Viking and began to account for its equity investment in Viking under the equity method. The Company owned an aggregate of 49.4% of the outstanding common stock of Viking at March 31, 2016. In January 2016, the Company entered into an amendment to the LSA with Viking to extend the maturity of the convertible loan to May 2017, reduce the interest rate from 5.0% to 2.5%, and extend the lock up period by one year such that the Company may not sell, transfer, or dispose of any Viking securities prior to January 2017. Additionally, upon the consummation of a subsequent capital financing transaction, Viking will be required to repay $1.5 million of the Viking Note obligation to the Company, with at least $0.3 million to be paid in cash and the remaining amount to be paid in the form and at the price of the Viking equity securities sold in the financing transaction. Upon maturity or further payments, the Company may elect to receive equity of Viking common stock or cash equal to 200% of the principal amount plus accrued and unpaid interest. The Company has opted to account for the Viking convertible note receivable at fair value. As of March 31, 2016, the aggregate fair market value of the note receivable was $4.8 million. For the three months ended March 31, 2016, the Company recorded a $15,000 decrease in the fair value of the Viking convertible note. See Note 2, Fair Value Measurements for additional details. |
Lease Obligations |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lease Obligations | Lease Obligations The Company leases office and laboratory facilities in California, Kansas and New Jersey. These leases expire between 2016 and 2023, some of which are subject to annual rent increases which range from 3.0% to 3.5%. The Company currently subleases office and laboratory space in California and New Jersey. The following table provides a summary of operating lease obligations and payments expected to be received from sublease agreements as of March 31, 2016 (in thousands):
As of March 31, 2016 and December 31, 2015, the Company had lease exit obligations of $0.6 million and $0.9 million, respectively. For the three months ended March 31, 2016 and 2015, the Company made cash payments, net of sublease payments received of $0.6 million and $0.9 million, respectively. The Company recognized adjustments for accretion and changes in leasing assumptions of $0.2 million for the three months ended March 31, 2016 and 2015. |
Financing Arrangements |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financing Arrangements | Financing Arrangements 0.75% Convertible Senior Notes Due 2019 In August 2014, the Company issued $245.0 million aggregate principal amount of its 2019 Convertible Senior Notes, resulting in net proceeds of $239.3 million. The 2019 Convertible Senior Notes are convertible into common stock at an initial conversion rate of 13.3251 shares per $1,000 principal amount of convertible notes, subject to adjustment upon certain events, which is equivalent to an initial conversion price of approximately $75.05 per share of common stock. The notes bear cash interest at a rate of 0.75% per year, payable semi-annually. Holders of the 2019 Convertible Senior Notes may convert the notes at any time prior to the close of business on the business day immediately preceding May 15, 2019, under any of the following circumstances: (1) during any fiscal quarter (and only during such fiscal quarter) commencing after December 31, 2014, if, for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of the Company's common stock on such trading day is greater than 130% of the conversion price on such trading day; (2) during the five business day period immediately following any ten consecutive trading day period, in which the trading price per $1,000 principal amount of notes was less than 98% of the product of the last reported sale price of the Company's common stock on such trading day and the conversion rate on each such trading day; or (3) upon the occurrence of certain specified corporate events as specified in the indenture governing the notes. On or after May 15, 2019 until the close of business on the second scheduled trading day immediately preceding August 15, 2019, holders of the notes may convert all or a portion of their notes at any time, regardless of the foregoing circumstances. Upon conversion, Ligand must deliver cash to settle the principal and may deliver cash or shares of common stock, at the option of the Company, to settle any premium due upon conversion. In accordance with accounting guidance for debt related to conversion and other options, the Company separately accounted for the debt and equity components of the 2019 Convertible Senior Notes by allocating the $245.0 million total proceeds between the debt component and the embedded conversion option, or equity component, due to Ligand's ability to settle the 2019 Convertible Senior Notes in cash for the principal portion and to settle any premium in cash or common stock, at the Company's election. The debt allocation was performed in a manner that reflected the Company's non-convertible borrowing rate for similar debt of 5.83% derived from independent valuation analysis. The initial debt value of $192.5 million accretes at 5.83% to reach $245.0 million at the maturity date. The equity component of the 2019 Convertible Senior Notes was recognized as a debt discount and represents the difference between the $245.0 million proceeds at issuance of the 2019 Convertible Senior Notes and the fair value of the debt allocation on their respective issuance dates. The debt discount is amortized to interest expense using the effective interest method over the expected life of a similar liability without an equity component. The notes will have a dilutive effect to the extent the average market price per share of common stock for a given reporting period exceeds the conversion price of $75.05. As of March 31, 2016, the “if-converted value” exceeded the principal amount of the 2019 Convertible Senior Notes by $104.6 million. In connection with the issuance of the 2019 Convertible Senior Notes, the Company incurred $5.7 million of issuance costs, which primarily consisted of underwriting, legal and other professional fees. The portions of these costs allocated to the equity components totaling $1.2 million were recorded as a reduction to additional paid-in capital. The portions of these costs allocated to the liability components totaling $4.5 million are recorded net of the liability component on the balance sheet beginning in 2016 in accordance with ASU 2015-03, Interest-Imputation of Interest: Simplifying the Presentation of Debt Issuance Costs. The portions allocated to the liability components are amortized to interest expense using the effective interest method over the expected life of the 2019 Convertible Senior Notes. The Company determined the expected life of the debt discount for the 2019 Convertible Senior Notes to be equal to the original five-year term of the notes. The carrying value of the equity component related to the 2019 Convertible Senior Notes as of March 31, 2016 and December 31, 2015, net of issuance costs, was $51.3 million. Convertible Bond Hedge and Warrant Transactions In August 2014, in connection with the issuance of the 2019 Convertible Senior Notes, to minimize the impact of potential dilution to the Company's common stock upon conversion of such notes, the Company entered into convertible bond hedges and sold warrants covering approximately 3,264,643 shares of its common stock. The convertible bond hedges have an exercise price of $75.05 per share and are exercisable when and if the 2019 Convertible Senior Notes are converted. If upon conversion of the 2019 Convertible Senior Notes, the price of the Company's common stock is above the exercise price of the convertible bond hedges, the counterparties will deliver shares of common stock and/or cash with an aggregate value approximately equal to the difference between the price of common stock at the conversion date and the exercise price, multiplied by the number of shares of common stock related to the convertible bond hedge transaction being exercised. The convertible bond hedges and warrants described below are separate transactions entered into by the Company and are not part of the terms of the 2019 Convertible Senior Notes. Holders of the 2019 Convertible Senior Notes and warrants will not have any rights with respect to the convertible bond hedges. The Company paid $48.1 million for these convertible bond hedges and recorded the amount as a reduction to additional paid-in capital. Concurrently with the convertible bond hedge transactions, the Company entered into warrant transactions whereby it sold warrants to acquire, approximately 3,264,643 shares of common stock with an exercise price of approximately $125.08 per share, subject to certain adjustments. The warrants have various expiration dates ranging from November 13, 2019 to April 22, 2020. The warrants will have a dilutive effect to the extent the market price per share of common stock exceeds the applicable exercise price of the warrants, as measured under the terms of the warrant transactions. The Company received $11.6 million for these warrants and recorded this amount to additional paid-in capital. The common stock issuable upon exercise of the warrants will be in unregistered shares, and the Company does not have the obligation and does not intend to file any registration statement with the SEC registering the issuance of the shares under the warrants. The carrying values and the fixed contractual coupon rates of the Company's financing arrangements as of March 31, 2016 and December 31, 2015 were as follows (in thousands):
|
Income Tax |
3 Months Ended |
---|---|
Mar. 31, 2016 | |
Income Tax Disclosure [Abstract] | |
Income Tax | Income Tax The Company's income tax provision from continuing operations for the three months ended March 31, 2016 was $3.7 million. The Company's income tax provision from discontinued operations for the three months ended March 31, 2016 was $0.4 million. The Company's income tax provision from continuing operations for the three months ended March 31, 2015 was $15,000. The Company estimates its annual effective income tax rate for continuing operations to be approximately 39.4% for 2016, compared to the 1.9% effective income tax rate for 2015. The estimated effective tax rate for 2016 is different from the federal statutory rate primarily as a result of significant permanent book-to-tax differences and state taxes. The permanent differences include non-taxable contingent consideration income (expense) recorded related to the change in market value of contingent liabilities. Any significant contingent consideration expense or income will result in a significantly higher or lower effective tax rate because contingent consideration expense is largely not deductible for tax purposes and contingent consideration income is not taxable. Other permanent differences between financial statement income and taxable income relate to items such as stock compensation, meals and entertainment charges, and compensation of officers. The primary difference in the estimated effective tax rate in 2016 compared to 2015 relates to the release of the Company’s valuation allowance in 2015. Our estimated annual effective tax rate for the three months ended March 31, 2015 is primarily attributable to an increase in our deferred tax liability associated with the tax amortization of acquired indefinite lived IPR&D intangible assets. The Company maintains a valuation allowance in the amount of $8.9 million against certain U.S. state NOLs, federal NOLs arising from Pre-ASC 718 excess stock compensation benefits and federal research and development tax credits. Each reporting period, the Company evaluates the need for a valuation allowance on our deferred tax assets by jurisdiction and adjusts our estimates as more information becomes available. The Company will reassess the ability to realize the deferred tax assets on a quarterly basis. If it is more likely than not that it will not realize the recognized deferred tax assets, then all or a portion of the valuation allowance may need to be re-established, which would result in a charge to tax expense. Conversely if new events indicate that it is more likely than not that we will realize additional deferred tax assets, then all or a portion of the remaining valuation allowance may be released, which would result in a tax benefit. As of March 31, 2016, the Company had unrecognized tax benefits of approximately $33.6 million related to uncertain tax positions that, if recognized, would result in adjustments to the related deferred tax assets and reduce our annual effective tax rate, subject to the remaining valuation allowance. The Company files income tax returns in the U.S. and in various state jurisdictions with varying statutes of limitations. The Company is no longer subject to income tax examination by tax authorities for years prior to 2011; however, its net operating loss and research credit carry-forwards arising prior to that year are subject to adjustment. It is the Company's policy to recognize interest expense and penalties related to income tax matters as a component of income tax expense. As of March 31, 2016, there was no material accrued interest related to uncertain tax positions. |
Stockholders' Equity |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders' Equity | Stockholders’ Equity The Company grants options and awards to employees and non-employee directors pursuant to a stockholder approved stock incentive plan, which is described in further detail in Note 8, Stockholders' Equity, of Notes to Consolidated Financial Statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015. The following is a summary of the Company’s stock option and restricted stock activity and related information:
Net cash received from options exercised during the three months ended March 31, 2016 and 2015 was approximately $1.0 million and $0.8 million, respectively. Tax deductions for stock options and restricted stock which have exceeded stock based compensation expense in previous years have not been recognized by the Company. The Company will monitor the utilization of the net operating losses and recognize the excess tax deduction when that deduction reduces taxes payable. As of March 31, 2016, 42,000 shares were available for future option grants or direct issuance under the Company's 2002 Stock Incentive Plan, as amended. Employee Stock Purchase Plan The Company's Amended ESPP allows participating employees to purchase up to 1,250 shares of Ligand common stock during each offering period, but in no event may a participant purchase more than 1,250 shares of common stock during any calendar year. The length of each offering period is six months, and employees are eligible to participate in the first offering period beginning after their hire date. This plan is described in further detail in Note 8, Stockholders' Equity, of Notes to Consolidated Financial Statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015. There were no shares of common stock issued under the amended ESPP during the three months ended March 31, 2016 and 2015, respectively. As of March 31, 2016, 72,367 shares were available for future purchases under the Amended ESPP. Issuance of common stock In conjunction with the acquisition of OMT, the Company issued 793,070 shares of its common stock based on a 20-day volume-weighted average price of $107.66 of its common stock calculated three days prior to closing. |
Litigation |
3 Months Ended |
---|---|
Mar. 31, 2016 | |
Commitments and Contingencies Disclosure [Abstract] | |
Litigation | Litigation The Company records an estimate of a loss when the loss is considered probable and estimable. Where a liability is probable and there is a range of estimated loss and no amount in the range is more likely than any other number in the range, The Company records the minimum estimated liability related to the claim in accordance with FASB ASC Topic 450 Contingencies. As additional information becomes available, the Company assesses the potential liability related to its pending litigation and revises its estimates. Revisions in the Company's estimates of potential liability could materially impact its results of operations. Securities Litigation In 2012, a federal securities class action and shareholder derivative lawsuit was filed in Pennsylvania alleging that the Company and its CEO assisted various breaches of fiduciary duties based on the Company’s purchase of a licensing interest in a development-stage pharmaceutical program from the Genaera Liquidating Trust in 2010 and the Company’s subsequent sale of half of its interest in the transaction to Biotechnology Value Fund, Inc. Plaintiff filed a second amended complaint in February 2015, which the Company moved to dismiss in March 2015. The district court granted the motion to dismiss on November 11, 2015. The plaintiff has appealed that ruling to the Third Circuit. The Company intends to continue to vigorously defend against the claims against the Company and its CEO. The outcome of the matter is not presently determinable. Paragraph IV Certification by Par Pharmaceuticals On January 7, 2016, the Company received a paragraph IV certification from Par Sterile Products, LLC, a subsidiary of Par Pharmaceuticals, Inc., or Par, advising us that it had filed an ANDA with the FDA seeking approval to market a generic version of Merck’s NOXAFIL-IV product. The paragraph IV certification states it is Par’s position that Merck’s U.S. Patent No. 9,023,790 related to NOXAFIL-IV and our U.S. Patent No. 8,410,077 related to Captisol are invalid and/or will not be infringed by Par’s manufacture, use or sale of the product for which the ANDA was submitted. On February 19, 2016, Merck filed an action against Par in the United States District Court for the District of New Jersey, asserting that Par’s manufacture, use or sale of the product for which the ANDA was submitted would infringe Merck’s U.S. Patent No. 9,023,790. The case against Par is captioned Merck Sharpe & Dohme Corp. v. Par Sterile Products, LLC, Par Pharmaceuticals, Inc., Par Pharmaceutical Companies, Inc., and Par Pharmaceutical Holdings, Inc., No.16-cv-00948. |
Subsequent Event |
3 Months Ended |
---|---|
Mar. 31, 2016 | |
Subsequent Events [Abstract] | |
Subsequent event | Subsequent events Viking On April 13, 2016, Viking closed its underwritten public offering of 7.5 million shares of common stock and warrants to purchase up to 7.5 million shares of its common stock at a price of $1.25 per share of its common stock and related warrants. The warrant has an exercise price of $1.50 per share, immediately exercisable and will expire on April 13, 2021. As part of this public offering, the Company purchased 560,000 shares of common stock and warrants to purchase 560,000 shares of Viking's common stock for a total purchase price of $0.7 million. The purchased shares of common stock and warrants are subject to the same terms as the shares issued in this offering. In addition, on April 13, 2016, pursuant to the terms of the amendment to the LSA that was entered in January 2016 between Ligand and Viking (see details in Note 4), Viking repaid $0.3 million of the convertible notes in cash, and issued the Company 960,000 shares of its common stock and warrants to purchase 960,000 shares of its common stock as repayment of $1.2 million of the convertible notes. The shares received as part of the repayment are subject to a lock-up period that ends on January 23, 2017 in accordance with the amended LSA. Our equity ownership of Viking decreased to approximately 38% after this public offering and the repayment of the convertible notes. Sublease In April 2016, the Company executed a sublease agreement for our current corporate headquarters facility in La Jolla, California. The sublease term will commence in May 2016 and expire in June 2019. The sublesee is obligated to pay a base rent of approximately $51,000 per month for the first twelve months and is subject to 3% annual increases through the sublease term. CorMatrix On May 3, 2016, the Company entered into an agreement to acquire certain economic rights of CorMatrix®. Pursuant to the Purchase Agreement, the Company paid $17.5 million in cash to acquire a portion of revenues (“synthetic royalties”) from CorMatrix’s existing marketed products and will have the right to receive potential future synthetic royalties from future marketed products, if any. Ligand is entitled to a minimum of $2.75 million of synthetic royalty annually. The synthetic royalty rate on the pipeline assets is a mid-single digit royalty. The agreement will terminate with respect to each of CorMatrix’s products upon the later of (i) May 3, 2026 and (ii) 10 years from the date of the first commercial sale of such product. Relationships between the Parties As previously disclosed in Ligand’s filings, Jason Aryeh is a director of both Ligand and CorMatrix. Mr. Aryeh beneficially owns equity of CorMatrix representing approximately .56% of CorMatrix’s outstanding equity. Mr. Aryeh recused himself from all of the board’s consideration of the Purchase Agreement, including any financial analysis, the terms of the Purchase Agreement and the vote to approve the Purchase Agreement and the related transactions. In addition, prior to the board’s consideration of the Purchase Agreement, Mr. David Knott, a member of Ligand’s board, disclosed to the board that he beneficially owns equity of CorMatrix representing approximately .47% of CorMatrix’s outstanding equity. All of the disinterested directors of Ligand approved the Purchase Agreement and related transactions with CorMatrix. |
Significant Accounting Policies (Policies) |
3 Months Ended |
---|---|
Mar. 31, 2016 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Principles of Consolidation | Principles of Consolidation The accompanying consolidated financial statements include Ligand and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. |
Basis of Presentation | Basis of Presentation The Company’s accompanying unaudited condensed consolidated financial statements as of March 31, 2016 and for the three months ended March 31, 2016 and 2015 have been prepared in accordance with GAAP for interim financial information. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position and results of operations of the Company and its subsidiaries, have been included. Operating results for the three months ended March 31, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. These financial statements should be read in conjunction with the consolidated financial statements and notes therein included in the Company’s annual report on Form 10-K/A for the year ended December 31, 2015 filed on November 14, 2016. |
Use of Estimates | Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires the use of estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. Actual results may differ from those estimates. |
Reclassifications | Reclassifications Certain reclassifications have been made to the previously issued balance sheet and statement of operations for the three months ended March 31, 2015 for comparability purposes. These reclassifications had no effect on the reported net income, stockholders' equity, and operating cash flows as previously reported. |
Income Per Share | Income Per Share Basic income per share is calculated by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted income per share is computed by dividing net income by the weighted-average number of common shares and common stock equivalents of all dilutive securities calculated using the treasury stock method and the if-converted method. |
Cash Equivalents and Short-term Investments | Cash Equivalents Cash equivalents consist of all investments with maturities of three months or less from the date of acquisition. Short-term Investments Short-term investments primarily consist of investments in debt securities that have effective maturities greater than three months and less than twelve months from the date of acquisition. The Company classifies its short-term investments as "available-for-sale". Such investments are carried at fair value, with unrealized gains and losses included in the statement of comprehensive income (loss). The Company determines the cost of investments based on the specific identification method. |
Restricted Investments | Restricted Investments Restricted investments consist of certificates of deposit held with a financial institution as collateral under a facility lease and third-party service provider arrangements. |
Inventory | Inventory Inventory, which consists of finished goods, is stated at the lower of cost or market value. The Company determines cost using the first-in, first-out method. Inventory levels are analyzed periodically and written down to its net realizable value if it has become obsolete, has a cost basis in excess of its expected net realizable value or is in excess of expected requirements. |
Goodwill and Other Identifiable Intangible Assets | Amortization of definite-lived intangible assets is computed using the straight-line method over the estimated useful life of the asset of 20 years. |
Commercial license rights | Commercial License Rights Commercial license rights represent a portfolio of future milestone and royalty payment rights acquired from Selexis in April 2013 and April 2015. Individual commercial license rights acquired under the agreement are carried at allocated cost and approximate fair value. The carrying value of the license rights will be reduced on a pro-rata basis as revenue is realized over the term of the agreement. Declines in the fair value of individual license rights below their carrying value that are deemed to be other than temporary are reflected in earnings in the period such determination is made. As of March 31, 2016, management does not believe there have been any events or circumstances indicating that the carrying amount of its commercial license rights may not be recoverable. |
Property and Equipment | Depreciation of equipment is computed using the straight-line method over the estimated useful lives of the assets, which range from three to ten years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful lives or the related lease term. |
Contingent Liabilities | Contingent Liabilities In connection with the Company’s acquisition of CyDex in January 2011, the Company recorded a contingent liability, for amounts potentially due to holders of the CyDex CVRs and former license holders. The liability is periodically assessed based on events and circumstances related to the underlying milestones, royalties and material sales. Any change in fair value is recorded in the Company’s consolidated statement of operations. The carrying amount of the liability may fluctuate significantly and actual amounts paid under the CVR agreements may be materially different than the carrying amount of the liability. The fair value of the liability at March 31, 2016 and December 31, 2015 was $6.9 million and $9.5 million, respectively. The Company recorded a fair-value adjustment to increase the liability by $0.2 million and $1.2 million for the three months ended March 31, 2016 and 2015, respectively. There was a revenue-sharing payment of $2.8 million and $3.2 million to CyDex CVR holders during the three months ended March 31, 2016 and 2015, respectively. In connection with the Company’s acquisition of Metabasis in January 2010, the Company issued to Metabasis stockholders four tradable CVRs, one CVR from each of four respective series of CVR, for each Metabasis share. The CVRs will entitle Metabasis stockholders to cash payments as frequently as every six months as cash is received by the Company from proceeds from the sale or partnering of any of the Metabasis drug development programs, among other triggering events. The fair values of the CVRs are remeasured at each reporting date through the term of the related agreement. Any change in fair value is recorded in the Company’s consolidated statement of operations. The carrying amount of the liability may fluctuate significantly based upon quoted market prices and actual amounts paid under the agreements may be materially different than the carrying amount of the liability. |
Revenue Recognition | Revenue Recognition Royalties on sales of products commercialized by the Company’s partners are recognized in the quarter reported to Ligand by the respective partner. Generally, the Company receives royalty reports from its licensees approximately one quarter in arrears due to the fact that its agreements require partners to report product sales between 30 and 60 days after the end of the quarter. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured. Under this accounting policy, the royalty revenues reported are not based upon estimates and such royalty revenues are typically reported to the Company by its partners in the same period in which payment is received. Revenue from material sales of Captisol is recognized upon transfer of title, which normally passes upon shipment to the customer, provided all other revenue recognition criteria have been met. All product returns are subject to the Company's credit and exchange policy, approval by the Company and a 20% restocking fee. To date, product returns by customers have not been material to net material sales in any related period. The Company records revenue net of product returns, if any, and sales tax collected and remitted to government authorities during the period. The Company analyzes its revenue arrangements and other agreements to determine whether there are multiple elements that should be separated and accounted for individually or as a single unit of accounting. For multiple element contracts, arrangement consideration is allocated at the inception of the arrangement to all deliverables on the basis of relative selling price, using a hierarchy to determine selling price. Management first considers VSOE, then TPE and if neither VSOE nor TPE exist, the Company uses its best estimate of selling price. Many of the Company's revenue arrangements for Captisol involve a license agreement with the supply of manufactured Captisol product. Licenses may be granted to pharmaceutical companies for the use of Captisol product in the development of pharmaceutical compounds. The supply of the Captisol product may be for all phases of clinical trials and through commercial availability of the host drug or may be limited to certain phases of the clinical trial process. Management believes that the Company's licenses have stand-alone value at the outset of an arrangement because the customer obtains the right to use Captisol in its formulations without any additional input by the Company. Other nonrefundable, upfront license fees are recognized as revenue upon delivery of the license, if the license is determined to have standalone value that is not dependent on any future performance by the Company under the applicable collaboration agreement. Nonrefundable contingent event-based payments are recognized as revenue when the contingent event is met, which is usually the earlier of when payments are received or collections are assured, provided that it does not require future performance by the Company. The Company occasionally has sub-license obligations related to arrangements for which it receives license fees, milestones and royalties. The Company evaluates the determination of gross versus net reporting based on each individual agreement. Sales-based contingent payments from partners are accounted for similarly to royalties, with revenue recognized upon achievement of the sales targets assuming all other revenue recognition criteria for milestones are met. Revenue from development and regulatory milestones is recognized when earned, as evidenced by written acknowledgement from the collaborator, provided that (1) the milestone event is substantive, its achievability was not reasonably assured at the inception of the agreement, and the Company has no further performance obligations relating to that event, and (2) collectability is reasonably assured. If these criteria are not met, the milestone payment is recognized over the remaining period of the Company’s performance obligations under the arrangement. Revenue from research funding under our collaboration agreements is earned and recognized on a percentage-of completion basis as research hours are incurred in accordance with the provisions of each agreement. |
Stock-Based Compensation | Stock-Based Compensation Stock-based compensation expense for awards to employees and non-employee directors is recognized on a straight-line basis over the vesting period until the last tranche vests. |
Income Taxes | Income Taxes Income taxes are accounted for under the liability method. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of differences between the tax basis of assets or liabilities and their carrying amounts in the consolidated financial statements. The Company provides a valuation allowance for deferred tax assets if it is more likely than not that these items will expire before we are able to realize their benefit. The Company calculates the valuation allowance in accordance with the authoritative guidance relating to income taxes under ASC 740, Income Taxes, which requires an assessment of both positive and negative evidence that is available regarding the reliability of these deferred tax assets, when measuring the need for a valuation allowance. Developing the provision for income taxes requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred tax assets and liabilities and, if necessary, any valuation allowances that may be required for deferred tax assets. The Company's judgments and tax strategies are subject to audit by various taxing authorities. While management believes the Company has provided adequately for its income tax liabilities in its consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the Company's consolidated financial condition and results of operations. |
Variable Interest Entities | Variable Interest Entities The Company identifies an entity as a VIE if either: (1) the entity does not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support, or (2) the entity's equity investors lack the essential characteristics of a controlling financial interest. The Company performs ongoing qualitative assessments of its VIEs to determine whether the Company has a controlling financial interest in any VIE and therefore is the primary beneficiary. If the Company is the primary beneficiary of a VIE, it consolidates the VIE under applicable accounting guidance. If the Company is no longer the primary of a VIE or the entity is no longer considered as a VIE as facts and circumstances changed, it deconsolidates the entity under the applicable accounting guidance. Beginning May 2015, the Company deconsolidated Viking, a previously reported VIE, and elected to record its investment in Viking under the equity method of accounting as Viking is no longer considered a VIE and the Company does not have voting control or other elements of control that would require consolidation. The investment is subsequently adjusted for the Company’s share of Viking's operating results, and if applicable, cash contributions and distributions, which is reported on a separate line in our condensed consolidated statement of operations called “Equity in net losses of Viking Therapeutics”. On the condensed consolidated balance sheet, the Company reports its investment in Viking on a separate line in the non-current assets section called “Investment in Viking Therapeutics”. |
Convertible Debt | Convertible Debt In August 2014, the Company completed a $245.0 million offering of 2019 Convertible Senior Notes, which bear interest at 0.75%. The Company accounts for the 2019 Convertible Senior Notes by separating the liability and equity components of the instrument in a manner that reflects the Company's nonconvertible debt borrowing rate. As a result, the Company assigned a value to the debt component of the 2019 Convertible Senior Notes equal to the estimated fair value of similar debt instruments without the conversion feature, which resulted in the Company recording the debt instrument at a discount. The Company is amortizing the debt discount over the life of the 2019 Convertible Senior Notes as additional non-cash interest expense utilizing the effective interest method. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements In May 2014, FASB issued ASU 2014-09, Revenue from Contracts with Customers. ASU 2014-09 is effective for annual periods beginning after December 15, 2016 and interim periods within those annual periods. The revenue standard’s core principle is built on the contract between a vendor and a customer for the provision of goods and services. It attempts to depict the exchange of rights and obligations between the parties in the pattern of revenue recognition based on the consideration to which the vendor is entitled. To accomplish this objective, the standard requires five basic steps: (1) identify the contract with the customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, (5) recognize revenue when (or as) the entity satisfies a performance obligation. Management is currently evaluating the effect the adoption of this standard will have on the Company's financial statements. In April 2015, FASB issued ASU 2015-03, Interest-Imputation of Interest: Simplifying the Presentation of Debt Issuance Costs. This update was issued to simplify the presentation for debt issuance costs. Upon adoption, such costs shall be presented on our consolidated balance sheets as a direct deduction from the carrying amount of the related debt liability and not as a deferred charge presented in Other assets on our consolidated balance sheets. This amendment will be effective for interim and annual periods beginning on January 1, 2016, and is required to be retrospectively adopted. During the three-month period ended March 31, 2016, management adopted the change in the presentation on our consolidated balance sheets accordingly (see Note 6 for details). In January 2016, the FASB issued ASU 2016-01 Recognition and Measurement of Financial Assets and Financial Liabilities that amends the accounting and disclosures of financial instruments, including a provision that requires equity investments (except for investments accounted for under the equity method of accounting) to be measured at fair value with changes in fair value recognized in current earnings. The new standard is effective for interim and annual periods beginning on January 1, 2018. We are currently evaluating the impact that this new standard will have on our consolidated financial statements. In February 2016, the FASB issued a new accounting standard that amends the guidance for the accounting and disclosure of leases. This new standard requires that lessees recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative information about their leasing arrangements. The new standard is effective for interim and annual periods beginning on January 1, 2019. We are currently evaluating the impact that this new standard will have on our consolidated financial statements. In March 2016, the FASB issued ASU 2016-09, Compensation – Stock Compensation, which identifies areas for simplification involving several aspects of accounting for stock-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, an option to recognize gross stock compensation expense with actual forfeitures recognized as they occur, as well as certain classifications on the statement of cash flows. ASU No. 2016-09 is effective for reporting periods beginning after December 31, 2016. Early adoption is permitted. We are currently assessing the potential impact that the adoption of ASU No. 2016-09 will have in our condensed consolidated financial statements. |
Significant Accounting Policies (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of computation of basic and diluted net income (loss) per share | The following table presents the computation of basic and diluted net income per share for the periods indicated (in thousands, except per share amounts):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of investment categories | The following table summarizes the various investment categories at March 31, 2016 and December 31, 2015 (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of goodwill and other identifiable intangible assets | Goodwill and other identifiable intangible assets consist of the following (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of property and equipment | Property and equipment is stated at cost and consists of the following (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of other current assets | Other current assets consist of the following (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of accrued liabilities | Accrued liabilities consist of the following (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of other long-term liabilities | Other long-term liabilities consist of the following (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule for accounting for share-based compensation | The following table summarizes stock-based compensation expense recorded as components of research and development expenses and general and administrative expenses for the periods indicated (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of fair-value options awarded to employees and directors | The fair-value for options that were awarded to employees and directors was estimated at the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions:
|
Business Combination (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Combinations [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Business Acquisitions by Acquisition, Consideration Transferred | The aggregate acquisition consideration was $174.0 million, consisting of (in thousands):
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed | he acquisition consideration was preliminarily allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Pro Forma Information | The following table presents supplemental pro forma information for the three months ended March 31, 2016 and March 31, 2015, as if the acquisition of OMT had occurred on January 1, 2015 (in thousands except for EPS):
|
Fair Value Measurements (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of the assets and liabilities measured at fair value on recurring basis | The following table provides a summary of the carrying value of assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2016 (in thousands). There were no transfers between Level 1 and Level 2 securities during the three months ended March 31, 2016:
The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2015 (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CyDex Acquisition | The following table represents significant unobservable inputs used in determining the fair value of contingent liabilities assumed in the acquisition of CyDex:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reconciliation of level 3 financial instruments | A reconciliation of the level 3 financial instruments as of March 31, 2016 is as follows (in thousands):
|
Lease Obligations (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments expected to received from sublease agreements | The following table provides a summary of operating lease obligations and payments expected to be received from sublease agreements as of March 31, 2016 (in thousands):
|
Financing Arrangements (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of carrying values and coupon rates on financing arrangements | The carrying values and the fixed contractual coupon rates of the Company's financing arrangements as of March 31, 2016 and December 31, 2015 were as follows (in thousands):
|
Stockholders' Equity (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock option plan activity | The following is a summary of the Company’s stock option and restricted stock activity and related information:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restricted stock activity | The following is a summary of the Company’s stock option and restricted stock activity and related information:
|
Significant Accounting Policies (Narrative) (Details) shares in Millions |
1 Months Ended | 3 Months Ended | 12 Months Ended | |||
---|---|---|---|---|---|---|
Jan. 08, 2016
USD ($)
|
Jan. 31, 2010
right
|
Mar. 31, 2016
USD ($)
shares
|
Mar. 31, 2015
USD ($)
shares
|
Dec. 31, 2015
USD ($)
|
Aug. 31, 2014
USD ($)
|
|
Earnings (Loss) Per Share | ||||||
Common shares excluded from computation | shares | 3.5 | 4.5 | ||||
Cash, Cash Equivalents and Short-term Investments | ||||||
Maturity period of cash and cash equivalents, maximum | 3 months | |||||
Maturity period of short term investments, minimum | 3 months | |||||
Inventory, Net [Abstract] | ||||||
Inventory write downs | $ 0 | $ 0 | ||||
Goodwill and Other Identifiable Intangible Assets | ||||||
Finite-lived intangible asset, useful life | 20 years | |||||
Amortization expense | $ 2,500,000 | 600,000 | ||||
Impairment of goodwill | 0 | 0 | ||||
Amortization Expense | ||||||
Amortization expense 2016 | 10,600,000 | |||||
Amortization expense 2017 | 10,700,000 | |||||
Amortization expense 2018 | 10,700,000 | |||||
Amortization expense 2019 | 10,700,000 | |||||
Amortization expense 2020 | 10,700,000 | |||||
Property and Equipment | ||||||
Depreciation | 100,000 | 100,000 | ||||
Contingent Liabilities | ||||||
Purchase of commercial license rights | $ 92,855,000 | 0 | ||||
Revenue Recognition | ||||||
Restocking fee (percent) | 20.00% | |||||
Minimum | ||||||
Revenue Recognition | ||||||
Period when partner sales reports are received after end of quarter | 30 days | |||||
Maximum | ||||||
Revenue Recognition | ||||||
Period when partner sales reports are received after end of quarter | 60 days | |||||
Equipment | Minimum | ||||||
Property and Equipment | ||||||
Estimated useful life of assets | 3 years | |||||
Equipment | Maximum | ||||||
Property and Equipment | ||||||
Estimated useful life of assets | 10 years | |||||
OMT, Inc. | ||||||
Property, Plant and Equipment [Line Items] | ||||||
Goodwill acquired | $ 60,800,000 | |||||
Finite-lived intangible assets | $ 167,000,000 | |||||
Cydex Pharmaceuticals, Inc | ||||||
Contingent Liabilities | ||||||
Fair value of liability | $ 6,900,000 | $ 9,500,000 | ||||
Contingent liability change in amount | 200,000 | 1,200,000 | ||||
Cydex Pharmaceuticals, Inc | Revenue Sharing | ||||||
Contingent Liabilities | ||||||
Purchase of commercial license rights | 2,800,000 | 3,200,000 | ||||
Metabasis Therapeutics | ||||||
Contingent Liabilities | ||||||
Fair value of liability | 2,400,000 | 4,000,000 | ||||
Contingent liability change in amount | (1,100,000) | 1,200,000 | ||||
Number of contingent value rights | right | 4 | |||||
Number of contingent value rights per series of contingent value rights | right | 1 | |||||
Number of contingent value rights issued for each share | right | 4 | |||||
Contingent value rights, frequency of cash payment | 6 months | |||||
Contingent liability, cash payment | 2,600,000 | 0 | ||||
Omthera Pharmaceuticals | ||||||
Milestone Payments | ||||||
Milestone payment received | 0 | |||||
2019 convertible senior notes | ||||||
Convertible Debt | ||||||
Principal amount outstanding | 245,000,000 | $ 245,000,000 | ||||
2019 convertible senior notes | Senior Notes | ||||||
Convertible Debt | ||||||
Principal amount outstanding | $ 245,000,000.0 | |||||
Interest rate | 0.75% | |||||
Acquired in-process research and development | ||||||
Goodwill and Other Identifiable Intangible Assets | ||||||
Impairment of IPR&D | $ 0 | $ 0 |
Significant Accounting Policies (Earnings (Loss) Per Share) (Details) - USD ($) $ / shares in Units, $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2016 |
Mar. 31, 2015 |
|
Summary of computation of basic and diluted net income (loss) per share | ||
Net income from continuing operations | $ 5,877 | $ (89) |
Net income from discontinued operations | 731 | 0 |
Net income: | $ 6,608 | $ 754 |
Shares used to compute basic income per share | 20,707,926 | 19,611,881 |
Dilutive potential common shares: | ||
Restricted stock | 66,736 | 61,538 |
Stock options | 759,581 | 957,369 |
0.75% Convertible Senior Notes, Due 2019 | 749,736 | 0 |
Shares used to compute diluted income per share | 22,283,979 | 20,630,788 |
Basic per share amounts: | ||
Income from continuing operations (in usd per share) | $ 0.28 | $ 0.04 |
Income from discontinued operations (in usd per share) | 0.04 | 0.00 |
Net income (in usd per share) | 0.32 | 0.04 |
Diluted per share amounts: | ||
Income from continuing operations (in usd per share) | 0.26 | 0.04 |
Income from discontinued operations (in usd per share) | 0.03 | 0.00 |
Net income (in usd per share) | $ 0.30 | $ 0.04 |
Significant Accounting Policies (Investment Categories) (Details) - USD ($) $ in Thousands |
Mar. 31, 2016 |
Dec. 31, 2015 |
---|---|---|
Summary of investment categories | ||
Amortized cost | $ 78,923 | $ 97,891 |
Gross unrealized gains | 2,988 | 4,944 |
Gross unrealized losses | (3) | (44) |
Estimated fair value | 81,908 | 102,791 |
Bank deposits | ||
Summary of investment categories | ||
Amortized cost | 42,376 | 43,043 |
Gross unrealized gains | 87 | 0 |
Gross unrealized losses | 0 | (4) |
Estimated fair value | 42,463 | 43,039 |
Corporate bonds | ||
Summary of investment categories | ||
Amortized cost | 24,268 | 41,238 |
Gross unrealized gains | 84 | 0 |
Gross unrealized losses | (2) | (35) |
Estimated fair value | 24,350 | 41,203 |
Commercial paper | ||
Summary of investment categories | ||
Amortized cost | 8,401 | 1,747 |
Gross unrealized gains | 2 | 0 |
Gross unrealized losses | 0 | 0 |
Estimated fair value | 8,403 | 1,747 |
Asset backed securities | ||
Summary of investment categories | ||
Amortized cost | 2,067 | 10,020 |
Gross unrealized gains | 1 | 0 |
Gross unrealized losses | (1) | (5) |
Estimated fair value | 2,067 | 10,015 |
Corporate equity securities | ||
Summary of investment categories | ||
Amortized cost | 1,811 | 1,843 |
Gross unrealized gains | 2,814 | 4,944 |
Gross unrealized losses | 0 | 0 |
Estimated fair value | $ 4,625 | $ 6,787 |
Significant Accounting Policies (Goodwill and Other Identifiable Intangible Assets) (Details) - USD ($) $ in Thousands |
Mar. 31, 2016 |
Dec. 31, 2015 |
---|---|---|
Summary of Goodwill and Other Identifiable Intangible Assets | ||
Goodwill | $ 72,997 | $ 12,238 |
Total goodwill and other identifiable intangible assets, net | 285,820 | 60,585 |
Complete technology | ||
Summary of Goodwill and Other Identifiable Intangible Assets | ||
Definite lived intangible assets | 182,267 | 15,267 |
Less: Accumulated amortization | (5,883) | (3,762) |
Trade name | ||
Summary of Goodwill and Other Identifiable Intangible Assets | ||
Definite lived intangible assets | 2,642 | 2,642 |
Less: Accumulated amortization | (685) | (652) |
Customer relationships | ||
Summary of Goodwill and Other Identifiable Intangible Assets | ||
Definite lived intangible assets | 29,600 | 29,600 |
Less: Accumulated amortization | (7,674) | (7,304) |
Acquired in-process research and development | ||
Summary of Goodwill and Other Identifiable Intangible Assets | ||
Acquired in-process research and development | $ 12,556 | $ 12,556 |
Significant Accounting Policies (Property and Equipment) (Details) - USD ($) $ in Thousands |
Mar. 31, 2016 |
Dec. 31, 2015 |
---|---|---|
Summary of Property and equipment | ||
Property and equipment , gross | $ 3,391 | $ 3,153 |
Less accumulated depreciation and amortization | (2,824) | (2,781) |
Total property and equipment, net | 567 | 372 |
Lab and office equipment | ||
Summary of Property and equipment | ||
Property and equipment , gross | 2,482 | 2,248 |
Leasehold improvements | ||
Summary of Property and equipment | ||
Property and equipment , gross | 273 | 273 |
Computer equipment and software | ||
Summary of Property and equipment | ||
Property and equipment , gross | $ 636 | $ 632 |
Significant Accounting Policies (Other Current Assets) (Details) - USD ($) $ in Thousands |
Mar. 31, 2016 |
Dec. 31, 2015 |
---|---|---|
Summary of other current assets | ||
Prepaid expenses | $ 1,087 | $ 1,177 |
Other receivables | 475 | 731 |
Total current assets | $ 1,562 | $ 1,908 |
Significant Accounting Policies (Accrued Liabilities and Other Long-Term Liabilities) (Details) - USD ($) $ in Thousands |
Mar. 31, 2016 |
Dec. 31, 2015 |
---|---|---|
Accrued Liabilities | ||
Compensation | $ 854 | $ 1,711 |
Professional fees | 754 | 726 |
Amounts owed to former licensees | 695 | 915 |
Royalties owed to third parties | 937 | 823 |
Other | 429 | 1,222 |
Total accrued liabilities | 3,669 | 5,397 |
Other Long-Term Liabilities | ||
Deposits | 298 | 268 |
Deferred rent | 107 | 0 |
Other | 41 | 29 |
Total other long-term liabilities | $ 446 | $ 297 |
Significant Accounting Policies (Accounting for Share-Based Compensation) (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2016 |
Mar. 31, 2015 |
|
Basis of Presentation [Line Items] | ||
Share-based compensation expense total | $ 4,118 | $ 2,914 |
Research and development expenses | ||
Basis of Presentation [Line Items] | ||
Share-based compensation expense total | 1,585 | 920 |
General and administrative expenses | ||
Basis of Presentation [Line Items] | ||
Share-based compensation expense total | $ 2,533 | $ 1,994 |
Significant Accounting Policies (Fair Value Valuation Assumptions) (Details) |
3 Months Ended | |
---|---|---|
Mar. 31, 2016 |
Mar. 31, 2015 |
|
Summary of fair-value options awarded to employees and directors | ||
Risk-free interest rate | 1.50% | 1.80% |
Dividend yield | 0.00% | 0.00% |
Expected volatility | 50.00% | 58.00% |
Expected term | 6 years 7 months 6 days | 6 years 6 months 22 days |
Forfeiture rate | 5.00% | 8.50% |
Business Combination (Details) $ in Thousands |
3 Months Ended | ||
---|---|---|---|
Jan. 08, 2016
USD ($)
program
platform
|
Mar. 31, 2016
USD ($)
|
Dec. 31, 2015
USD ($)
|
|
Business Acquisition [Line Items] | |||
Finite-lived intangible asset, useful life | 20 years | ||
Goodwill | $ 72,997 | $ 12,238 | |
OMT, Inc. | |||
Business Acquisition [Line Items] | |||
Number of transgenic animal platforms | platform | 3 | ||
Number of partnered programs added | program | 16 | ||
Consideration transferred | $ 174,000 | ||
Period for certain post-closing adjustments | 15 months | ||
Goodwill | $ 60,759 | ||
Core Technology | OMT, Inc. | |||
Business Acquisition [Line Items] | |||
Projected cash flow discount rate (percent) | 15.50% | ||
Finite-lived intangible asset, useful life | 20 years |
Business Combination - Consideration Transferred (Details) - OMT, Inc. $ / shares in Units, $ in Thousands |
Jan. 08, 2016
USD ($)
$ / shares
shares
|
---|---|
Business Acquisition [Line Items] | |
Cash consideration | $ 96,359 |
Total share consideration: | |
Actual number of shares issued (shares) | shares | 793,070 |
Multiplied by: Ligand closing share price on January 8, 2016 | $ / shares | $ 97.92 |
Total share consideration | $ 77,658 |
Total consideration | $ 174,017 |
Business Combination - Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands |
Mar. 31, 2016 |
Jan. 08, 2016 |
Dec. 31, 2015 |
---|---|---|---|
Business Acquisition [Line Items] | |||
Goodwill | $ 72,997 | $ 12,238 | |
OMT, Inc. | |||
Business Acquisition [Line Items] | |||
Cash and cash equivalents | $ 3,504 | ||
Accounts receivable | 5 | ||
Income tax receivable | 140 | ||
Prepaid expenses and other current assets | 2 | ||
Deferred tax liabilities, net | (56,114) | ||
Intangible asset with finite life - core technology | 167,000 | ||
Liabilities assumed | (1,279) | ||
Goodwill | 60,759 | ||
Total consideration | $ 174,017 |
Business Combination - Pro Forma Information (Details) - OMT, Inc. - USD ($) $ / shares in Units, $ in Thousands |
3 Months Ended | ||
---|---|---|---|
Jan. 07, 2016 |
Mar. 31, 2016 |
Mar. 31, 2015 |
|
Business Acquisition [Line Items] | |||
Revenue | $ 32,124 | $ 17,152 | |
Net income | $ 8,877 | $ (474) | |
Basic earnings per share (in USD per share): | $ 0.43 | $ (0.02) | |
Diluted earnings per share (in USD per share): | $ 0.40 | $ (0.02) | |
Pro forma adjustment for share-based compensation expense of OMT | $ 300 | ||
Pro forma adjustment for additional intangible amortization expense | $ 200 | $ 2,100 | |
Pro forma adjustment for license revenue recognized by OMT in the current period prior to the acquisition | $ 2,500 |
Fair Value Measurements (Details) - USD ($) |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2016 |
Dec. 31, 2015 |
Aug. 31, 2014 |
|
2019 convertible senior notes | |||
Liabilities: | |||
Principal amount outstanding | $ 245,000,000 | $ 245,000,000 | |
2019 convertible senior notes | Senior Notes | |||
Liabilities: | |||
Estimated fair value of debt | 373,500,000 | ||
Principal amount outstanding | $ 245,000,000.0 | ||
Recurring | |||
Assets: | |||
Assets, fair value | 91,991,000 | 100,572,000 | |
Liabilities: | |||
Liabilities, fair value | 9,841,000 | 14,241,000 | |
Recurring | Current contingent liabilities-CyDex | |||
Liabilities: | |||
Liabilities, fair value | 5,285,000 | 7,812,000 | |
Recurring | Current contingent liabilities-Metabasis | |||
Liabilities: | |||
Liabilities, fair value | 2,602,000 | ||
Recurring | Long-term contingent liabilities-Metabasis | |||
Liabilities: | |||
Liabilities, fair value | 2,444,000 | 1,355,000 | |
Recurring | Long-term contingent liabilities-CyDex | |||
Liabilities: | |||
Liabilities, fair value | 1,578,000 | 1,678,000 | |
Recurring | Liability for amounts owed to former licensees | |||
Liabilities: | |||
Liabilities, fair value | 534,000 | 794,000 | |
Recurring | Cash Equivalents | |||
Assets: | |||
Assets, fair value | 5,316,000 | 3,015,000 | |
Recurring | Short-term investments | |||
Assets: | |||
Assets, fair value | $ 81,908,000 | 92,775,000 | |
Recurring | Note receivable Viking Therapeutics, Inc. | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Estimated volatility of common stock | 50.00% | ||
Assets: | |||
Assets, fair value | $ 4,767,000 | 4,782,000 | |
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | |||
Assets: | |||
Assets, fair value | 4,625,000 | 6,786,000 | |
Liabilities: | |||
Liabilities, fair value | 534,000 | 794,000 | |
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Current contingent liabilities-CyDex | |||
Liabilities: | |||
Liabilities, fair value | 0 | 0 | |
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Current contingent liabilities-Metabasis | |||
Liabilities: | |||
Liabilities, fair value | 0 | ||
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Long-term contingent liabilities-Metabasis | |||
Liabilities: | |||
Liabilities, fair value | 0 | 0 | |
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Long-term contingent liabilities-CyDex | |||
Liabilities: | |||
Liabilities, fair value | 0 | 0 | |
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Liability for amounts owed to former licensees | |||
Liabilities: | |||
Liabilities, fair value | 534,000 | 794,000 | |
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Cash Equivalents | |||
Assets: | |||
Assets, fair value | 0 | 0 | |
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term investments | |||
Assets: | |||
Assets, fair value | 4,625,000 | 6,786,000 | |
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Note receivable Viking Therapeutics, Inc. | |||
Assets: | |||
Assets, fair value | 0 | 0 | |
Recurring | Significant Other Observable Inputs (Level 2) | |||
Assets: | |||
Assets, fair value | 82,599,000 | 89,004,000 | |
Liabilities: | |||
Liabilities, fair value | 2,444,000 | 3,957,000 | |
Recurring | Significant Other Observable Inputs (Level 2) | Current contingent liabilities-CyDex | |||
Liabilities: | |||
Liabilities, fair value | 0 | 0 | |
Recurring | Significant Other Observable Inputs (Level 2) | Current contingent liabilities-Metabasis | |||
Liabilities: | |||
Liabilities, fair value | 2,602,000 | ||
Recurring | Significant Other Observable Inputs (Level 2) | Long-term contingent liabilities-Metabasis | |||
Liabilities: | |||
Liabilities, fair value | 2,444,000 | 1,355,000 | |
Recurring | Significant Other Observable Inputs (Level 2) | Long-term contingent liabilities-CyDex | |||
Liabilities: | |||
Liabilities, fair value | 0 | 0 | |
Recurring | Significant Other Observable Inputs (Level 2) | Liability for amounts owed to former licensees | |||
Liabilities: | |||
Liabilities, fair value | 0 | 0 | |
Recurring | Significant Other Observable Inputs (Level 2) | Cash Equivalents | |||
Assets: | |||
Assets, fair value | 5,316,000 | 3,015,000 | |
Recurring | Significant Other Observable Inputs (Level 2) | Short-term investments | |||
Assets: | |||
Assets, fair value | 77,283,000 | 85,989,000 | |
Recurring | Significant Other Observable Inputs (Level 2) | Note receivable Viking Therapeutics, Inc. | |||
Assets: | |||
Assets, fair value | 0 | 0 | |
Recurring | Significant Unobservable Inputs (Level 3) | |||
Assets: | |||
Assets, fair value | 4,767,000 | 4,782,000 | |
Liabilities: | |||
Liabilities, fair value | 6,863,000 | 9,490,000 | |
Recurring | Significant Unobservable Inputs (Level 3) | Current contingent liabilities-CyDex | |||
Liabilities: | |||
Liabilities, fair value | 5,285,000 | 7,812,000 | |
Recurring | Significant Unobservable Inputs (Level 3) | Current contingent liabilities-Metabasis | |||
Liabilities: | |||
Liabilities, fair value | 0 | ||
Recurring | Significant Unobservable Inputs (Level 3) | Long-term contingent liabilities-Metabasis | |||
Liabilities: | |||
Liabilities, fair value | 0 | 0 | |
Recurring | Significant Unobservable Inputs (Level 3) | Long-term contingent liabilities-CyDex | |||
Liabilities: | |||
Liabilities, fair value | 1,578,000 | 1,678,000 | |
Recurring | Significant Unobservable Inputs (Level 3) | Liability for amounts owed to former licensees | |||
Liabilities: | |||
Liabilities, fair value | 0 | 0 | |
Recurring | Significant Unobservable Inputs (Level 3) | Cash Equivalents | |||
Assets: | |||
Assets, fair value | 0 | 0 | |
Recurring | Significant Unobservable Inputs (Level 3) | Short-term investments | |||
Assets: | |||
Assets, fair value | 0 | 0 | |
Recurring | Significant Unobservable Inputs (Level 3) | Note receivable Viking Therapeutics, Inc. | |||
Assets: | |||
Assets, fair value | 4,767,000 | $ 4,782,000 | |
Viking Therapeutics, Inc. | |||
Liabilities: | |||
Market value of investment in Viking | $ 6,800,000 |
Fair Value Measurements (Acquisition of CyDex) (Details) - Cydex Pharmaceuticals, Inc - USD ($) $ in Millions |
3 Months Ended | 12 Months Ended |
---|---|---|
Mar. 31, 2016 |
Dec. 31, 2015 |
|
Credit Derivatives [Line Items] | ||
Amount Of Revenue For Contingent Consideration | $ 15.0 | |
Contingent Consideration Classified as Equity | ||
Credit Derivatives [Line Items] | ||
Range of annual revenue subject to revenue sharing | $ 23.5 | $ 22.5 |
Revenue volatility | 25.00% | 25.00% |
Average of probability of commercialization | 78.00% | 73.00% |
Sales beta | 0.30 | 0.40 |
Credit rating | BB | BB |
Equity risk premium | 6.00% | 6.00% |
Fair Value Measurements (Level 3 Reconciliation) (Details) $ in Thousands |
3 Months Ended |
---|---|
Mar. 31, 2016
USD ($)
| |
Assets: | |
Fair value of level 3 financial instrument assets as of December 31, 2015 | $ 4,782 |
Viking note receivable fair market value adjustment | (15) |
Fair value of level 3 financial instrument assets as of March 31, 2016 | 4,767 |
Liabilities: | |
Fair value of level 3 financial instrument liabilities as of December 31, 2015 | 9,490 |
Payments to CVR and other former license holders | (2,828) |
Fair value adjustments to contingent liabilities | 201 |
Fair value of level 3 financial instrument liabilities as of March 31, 2016 | $ 6,863 |
Investment in Viking Therapeutics, Inc. (Details) $ / shares in Units, $ in Thousands, shares in Millions |
1 Months Ended | 3 Months Ended | 13 Months Ended | ||||
---|---|---|---|---|---|---|---|
Jan. 31, 2016
USD ($)
|
May 31, 2015
USD ($)
$ / shares
shares
|
May 31, 2014
USD ($)
program
|
Mar. 31, 2016
USD ($)
|
Mar. 31, 2015
USD ($)
|
May 31, 2015
$ / shares
|
Dec. 31, 2015
USD ($)
|
|
Schedule of Equity Method Investments [Line Items] | |||||||
Note receivable from Viking Therapeutics | $ 4,767 | $ 4,782 | |||||
Change in fair value of the convertible debt receivable from Viking | $ 15 | $ 0 | |||||
Viking | |||||||
Schedule of Equity Method Investments [Line Items] | |||||||
Number of programs licensed | program | 5 | ||||||
Loss percentage recorded | 100.00% | ||||||
Debt | Viking | |||||||
Schedule of Equity Method Investments [Line Items] | |||||||
Convertible loan facility | $ 2,500 | ||||||
Viking Therapeutics, Inc. | |||||||
Schedule of Equity Method Investments [Line Items] | |||||||
Equity interest in outstanding common stock of Viking (percent) | 49.40% | ||||||
Note receivable, stated interest rate (percent) | 2.50% | 5.00% | |||||
LSA, lock-up period extension | 1 year | ||||||
Note receivable, amount due upon consummation of capital financing transaction | $ 1,500 | ||||||
Note receivable, cash due upon consummation of capital financing transaction | $ 300 | ||||||
Note receivable, repayment in equity (percent) | 200.00% | ||||||
Common Stock | |||||||
Schedule of Equity Method Investments [Line Items] | |||||||
Aggregate value of shares received under licensing agreement | $ 29,200 | ||||||
IPO shares purchased by the Company (shares) | shares | 1.1 | ||||||
Payments to acquire IPO shares | $ 9,000 | ||||||
Common Stock | Viking Therapeutics, Inc. | IPO | |||||||
Schedule of Equity Method Investments [Line Items] | |||||||
Shares issued in IPO (shares) | shares | 3.7 | ||||||
IPO aggregate offering price | $ 29,200 | ||||||
IPO share price (USD per share) | $ / shares | $ 8.00 | $ 8.00 |
Lease Obligations (Narrative) (Details) - USD ($) $ in Thousands |
3 Months Ended | 12 Months Ended | |
---|---|---|---|
Mar. 31, 2016 |
Mar. 31, 2015 |
Dec. 31, 2015 |
|
Operating Leased Assets [Line Items] | |||
Lease expiration year, minimum | 2016 | ||
Lease expiration year, maximum | 2023 | ||
Percentage of increase in annual base rent, minimum | 3.00% | ||
Percentage of increase in annual base rent, maximum | 3.50% | ||
Lease exit costs | $ 244 | $ 223 | |
Rent expense, net sublease income | 600 | 900 | |
Adjustment for accretion and changes in lease assumptions | 200 | $ 200 | |
Contract Termination | |||
Operating Leased Assets [Line Items] | |||
Lease exit costs | $ 600 | $ 900 |
Lease Obligations (Lease Obligations) (Details) $ in Thousands |
Mar. 31, 2016
USD ($)
|
---|---|
Operating Leased Assets [Line Items] | |
Operating lease obligations, Less than 1 year | $ 1,899 |
Operating lease obligations, Future Minimum Payments, 1-2 years | 1,767 |
Operating lease obligations, 3-4 years | 464 |
Operating lease obligations, Thereafter | 306 |
Operating lease obligations, Total | 4,436 |
Payments expected to received from sublease agreements | |
Sublease payments expected to be received, Less than 1 year | 1,368 |
Sublease payments expected to be received, 1-2 years | 847 |
Sublease payments expected to be received, 3-4 years | 348 |
Sublease payments expected to be received, Thereafter | 306 |
Sublease payments expected to be received, Total | 2,869 |
CALIFORNIA | Corporate Headquarters - La Jolla | |
Operating Leased Assets [Line Items] | |
Operating lease obligations, Less than 1 year | 704 |
Operating lease obligations, Future Minimum Payments, 1-2 years | 1,465 |
Operating lease obligations, 3-4 years | 187 |
Operating lease obligations, Total | 2,356 |
Payments expected to received from sublease agreements | |
Sublease payments expected to be received, Less than 1 year | 443 |
Sublease payments expected to be received, 1-2 years | 920 |
Sublease payments expected to be received, 3-4 years | 116 |
Sublease payments expected to be received, Total | 1,479 |
CALIFORNIA | Corporate Headquarters - San Diego, CA | |
Operating Leased Assets [Line Items] | |
Operating lease obligations, Less than 1 year | 52 |
Operating lease obligations, Future Minimum Payments, 1-2 years | 261 |
Operating lease obligations, 3-4 years | 277 |
Operating lease obligations, Thereafter | 306 |
Operating lease obligations, Total | 896 |
KANSAS | Bioscience and Technology Business Center - Lawrence, KS | |
Operating Leased Assets [Line Items] | |
Operating lease obligations, Less than 1 year | 54 |
Operating lease obligations, Future Minimum Payments, 1-2 years | 41 |
Operating lease obligations, Total | 95 |
NEW JERSEY | Vacated Office Office and Research Facility - Cranbury, NJ | |
Operating Leased Assets [Line Items] | |
Operating lease obligations, Less than 1 year | 1,089 |
Operating lease obligations, Total | 1,089 |
NEW JERSEY | Office and Research Facility Cranbury | |
Payments expected to received from sublease agreements | |
Sublease payments expected to be received, Less than 1 year | 88 |
Sublease payments expected to be received, Total | $ 88 |
Financing Arrangements (Narrative) (Details) |
1 Months Ended | 3 Months Ended | |
---|---|---|---|
Aug. 31, 2014
USD ($)
d
$ / shares
shares
|
Mar. 31, 2016
USD ($)
|
Dec. 31, 2015
USD ($)
|
|
Debt Instrument [Line Items] | |||
Initial debt value | $ 204,653,000 | $ 201,985,000 | |
Common stock, shares available to be issued | shares | 3,264,643 | ||
Exercise price of convertible bond hedge | $ / shares | $ 75.05 | ||
Exercise price | $ / shares | $ 125.08 | ||
Proceeds from issuance of warrants | $ 11,600,000 | ||
2019 convertible senior notes | |||
Debt Instrument [Line Items] | |||
Aggregate principal amount outstanding | 245,000,000 | 245,000,000 | |
Initial debt value | 207,831,000 | 205,372,000 | |
Senior Notes | |||
Debt Instrument [Line Items] | |||
Payment for convertible bond hedges | $ 48,100,000 | ||
Senior Notes | 2019 convertible senior notes | |||
Debt Instrument [Line Items] | |||
Interest rate | 0.75% | ||
Aggregate principal amount outstanding | $ 245,000,000.0 | ||
Net proceeds from note after debt issuance costs | $ 239,300,000 | ||
Initial conversion rate | 0.0133251 | ||
Initial conversion price | $ / shares | $ 75.05 | ||
Proceeds from issuance of debt | $ 245,000,000 | ||
Debt discount rate | 5.83% | ||
Initial debt value | $ 192,500,000 | ||
If-converted value in excess of principal | 104,600,000 | ||
Debt issuance costs | 5,700,000 | ||
Equity component of convertible debt recorded as a reduction to additional paid-in capital | 1,200,000 | ||
Long-term debt issuance costs | $ 4,500,000 | ||
Term of notes | 5 years | ||
Carrying value of the equity component of debt, net of issuance costs | $ 51,300,000 | $ 51,300,000 | |
Senior Notes | 2019 convertible senior notes | Debt Instrument, Redemption, Period One | |||
Debt Instrument [Line Items] | |||
Threshold trading days | d | 20 | ||
Consecutive trading days | 30 days | ||
Percentage of stock price trigger | 130.00% | ||
Senior Notes | 2019 convertible senior notes | Debt Instrument, Redemption, Period Two | |||
Debt Instrument [Line Items] | |||
Threshold trading days | d | 5 | ||
Consecutive trading days | 10 days | ||
Maximum threshold percentage of debt trading price trigger | 98.00% |
Financing Arrangements (Notes Payable) (Details) - USD ($) $ in Thousands |
Mar. 31, 2016 |
Dec. 31, 2015 |
---|---|---|
Notes Payable, Current and Noncurrent [Abstract] | ||
Net carrying amount | $ 204,653 | $ 201,985 |
2019 convertible senior notes | ||
Notes Payable, Current and Noncurrent [Abstract] | ||
Principal amount outstanding | 245,000 | 245,000 |
Unamortized discount | (37,169) | (39,628) |
Net carrying amount | 207,831 | 205,372 |
Less: Unamortized deferred financing costs | 3,178 | 3,387 |
Total notes payable | $ 204,653 | $ 201,985 |
Income Tax (Details) - USD ($) $ / shares in Units, $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2016 |
Mar. 31, 2015 |
|
Income Tax Disclosure [Abstract] | ||
Income tax provision | $ 3,694 | $ 15 |
Income tax provision, per diluted share (in USD per share) | $ 0.17 | $ 0.00 |
Income tax provision from discontinued operation | $ 400 | |
Income tax provision, discontinued operation, per diluted share (in USD per share) | $ 0.02 | |
Effective income tax rate, continuing operations (percent) | 39.40% | 1.90% |
Valuation allowance | $ 8,900 | |
Unrecognized tax benefits | $ 33,600 |
Stockholders' Equity (Stock Option Plan and Restricted Stock Activity) (Details) |
3 Months Ended |
---|---|
Mar. 31, 2016
$ / shares
shares
| |
Stock Options: | |
Balance as of December 31, 2015 | shares | 1,683,341 |
Granted | shares | 241,015 |
Exercised | shares | (44,029) |
Balance as of March 31, 2016 | shares | 1,880,327 |
Weighted Average Exercise Price (in USD per share) | |
Balance as of December 31, 2015 | $ / shares | $ 34.23 |
Granted | $ / shares | 88.84 |
Exercised | $ / shares | 23.00 |
Balance as of March 31, 2016 | $ / shares | $ 41.50 |
Restricted Stock [Member] | |
Restricted Shares: | |
Nonvested at December 31, 2015 | shares | 130,749 |
Granted | shares | 229,847 |
Exercised | shares | (34,649) |
Nonvested at March 31, 2016 | shares | 325,947 |
Weighted- Average Grant Date Fair Value (in USD per share) | |
Nonvested at December 31, 2015 | $ / shares | $ 60.36 |
Granted | $ / shares | 94.76 |
Exercised | $ / shares | 52.18 |
Nonvested at March 31, 2016 | $ / shares | $ 72.88 |
Stockholders' Equity (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions |
3 Months Ended | ||
---|---|---|---|
Jan. 08, 2016 |
Mar. 31, 2016 |
Mar. 31, 2015 |
|
2002 Stock Incentive Plan | Stock Options | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Shares available for future option grants | 42,000 | ||
Employee Stock Purchase Plan | |||
Employee Stock Purchase Plan | |||
Shares allowed to purchase in employee stock purchase plan | 1,250 | ||
Shares issued in period | 0 | 0 | |
Shares available for future purchases | 72,367 | ||
Employee Stock Purchase Plan | Stock Options | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Net proceeds from employee stock purchase plan | $ 1.0 | $ 0.8 | |
OMT, Inc. | |||
Employee Stock Purchase Plan | |||
Common stock issued in acquisition (shares) | 793,070 | ||
20-day volume-weighted average price of common stock issued in acquisition (usd per share) | $ 107.66 |
Subsequent Event (Details) - USD ($) $ / shares in Units, $ in Thousands |
1 Months Ended | 3 Months Ended | 12 Months Ended | ||||
---|---|---|---|---|---|---|---|
May 03, 2016 |
Apr. 13, 2016 |
Apr. 30, 2016 |
Mar. 31, 2016 |
Mar. 31, 2015 |
Dec. 31, 2016 |
Aug. 31, 2014 |
|
Subsequent Event [Line Items] | |||||||
Warrants issued is public offering (shares) | 3,264,643 | ||||||
Warrant exercise price (USD per share) | $ 125.08 | ||||||
Annual royalty revenue | $ 14,390 | $ 10,287 | |||||
Corporate Headquarters - La Jolla | Subsequent Event | |||||||
Subsequent Event [Line Items] | |||||||
Rent expense | $ 51 | ||||||
Annual increase in rent expense (percent) | 3.00% | ||||||
Viking Therapeutics, Inc. | Subsequent Event | |||||||
Subsequent Event [Line Items] | |||||||
Shares issued in public offering (shares) | 7,500,000 | ||||||
Warrants issued is public offering (shares) | 7,500,000 | ||||||
Public offering share price (USD per share) | $ 1.25 | ||||||
Warrant exercise price (USD per share) | $ 1.50 | ||||||
Public offering shares purchased by the Company (shares) | 560,000 | ||||||
Public offering warrants purchased by the Company (USD per share) | 560,000 | ||||||
Payments to acquire public offering shares and warrants | $ 700 | ||||||
Proceeds from collection of note receivable | $ 300 | ||||||
Shares received for repayment of note receivable (shares) | 960,000 | ||||||
Warrants received for repayment of note receivable (shares) | 960,000 | ||||||
Value of shares and warrants received for repayment of note receivable | $ 1,200 | ||||||
Ownership percentage in Viking after public offering and repayment of convertible notes | 38.00% | ||||||
Synthetic Royalties | Subsequent Event | |||||||
Subsequent Event [Line Items] | |||||||
Payments to Acquire Intangible Assets | $ 17,500 | ||||||
Royalty Agreement, Expiration Period | 10 years | ||||||
Minimum | Scenario, Forecast | Synthetic Royalties | |||||||
Subsequent Event [Line Items] | |||||||
Annual royalty revenue | $ 2,750 | ||||||
Mr. Aryeh, Director | CorMatrix | Subsequent Event | |||||||
Subsequent Event [Line Items] | |||||||
Equity of CorMatrix beneficially owned by Ligand director | 0.56% | ||||||
Mr. Knott, Director | CorMatrix | Subsequent Event | |||||||
Subsequent Event [Line Items] | |||||||
Equity of CorMatrix beneficially owned by Ligand director | 0.47% |
)^;=YE=7X*8?=
MA7]+9FP9FA^6?ZPH]__X+#LO<6W[JZ"?S([!^F!C*N?::C/L&]63"ZM?SJV^
M "Y-A$WX-9):;>6"\7SA_-XL?[2F$Q@*AI%%& >OA3EX(I49(
M@_\LFO^1IG [?ZA_L[O5[B]8DA=.?P^MZK59& 8MZ?"-JC<^?R?+%C(CV' J
M[3-H;E)Q]B@) X8_W#B,=IS=FP(N9?L%\5(0KP4)LL8=R-K\BA6N*\'G0+C6
M3MA\P>@8ZT8T@;1!X7:OC4H=O==I%%7@;H26G-CFG/V<>,T!6G^%Q'N0Q$'B
MK0#\1"#9$TB=0.(Y2'R7R+ET.:/-*?,D*_ L_#'525.WIB-')3+I694-9;F09! 6XZT*2)
M1LW34A.Y%)6E@+,$*("9(G)10$,1612A.P!T!8A- &@%6$$BDX;1= 8RB-,$
MNF25+0OS+''CQ!LX\0('1I_DDVP4)/F?@J0;!*E%L"I(:@J2+C.-DV"]_496
M;<@L'+2!@ZQ\H!,'+=;Y E&8YDX<6Y:G4>;&R39PLJW?9<+)K/\ 93!TXMBR
M!*+(C9-OX.063NS$R1?KP!!E3AA+!#/D1M&WVZX
M#R"(SGV03%J%ELN3ZXA4M!>7SC5@D]5'U_5"7:OQ!:_*GIWX+R9/=:>BG="F
M87'=Q5$(SBFN0$Z"X-86,0IB"'/
M\#"&=65CKZ*N^$W1822O(I WQK#X>R:4SZCU6Y6,_:+_;Z*+PFWVY/:QOKOK/OAUOKNJW9K<]5-^.J]/;?E\>
M__U:[>KWZ[5:3Q]\WSZ_--T'FYNKS7G:3K3:?5AI- ^[S^Z$7#2VR=I.
M9_;OU]<,94%-]B6VR2E.07$.B/7=UM^;LS%M]*,LJN9M=6[;ZVL<-_NS*?/F
MQ5Y-U?USM'69M]UG?8J;:VWRPQ!4%C$PEL9E?JE6F_70]K7>K.VM+2Z5^5I'
MS:TL\_K?=U/8^]N*K^:&;Y?3N>T;XLTZ?L0=+J6IFHNMHMH